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The role of IFN-γ signaling pathway in cancer is conventionally associated with 
immune surveillance and tumor suppression by inducing the transcription of a wide 
range of IFN-γ regulated genes. In this study, we have identified IFNGR1 and 
components of the IFN-γ signaling pathway to be down regulated in advanced 
prostate cancer, luminal breast cancer, small cell and metastatic lung cancers, and 
high grade liver cancer. Importantly, we found that the expression of IFNGR1 was 
inversely correlated with the expression of EZH2 and MYC as the disease transits 
from benign prostate tissue to the high grade metastatic prostate cancer. Using MYC-
driven prostate cancer as a model, we show that Interferon Gamma Receptor 1 
(IFNGR1) is directly repressed by EZH2. EZH2 knockdown restored the expression 
of IFNGR1, when combined with interferon γ (IFN-γ) treatment, led to strong 
activation of IFN-STAT1 tumor suppressor pathway and robust apoptosis. 
Pharmacologic depletion of EZH2 by histone methylation inhibitor DZNep mimicked 
the EZH2 knockdown on IFNGR1 induction and synergistic effect with IFN-γ, 
whereas an EZH2 enzymatic inhibitor, though efficiently depleting histone Lysine 27 
trimethylation but not EZH2, failed to do so. Furthermore, we found that EZH2-
mediated IFNGR1 silencing occurs widely in human malignances whereby this 
combination consistently induced robust apoptosis. Thus, we identify an EZH2-
inactivated IFN-signaling in human cancers, and patients carrying this deregulation 
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1. 1 Prostate Cancer 
The prostate is a small walnut shaped gland that is situated in front of the rectum and 
below the bladder (Figure 1.1). The function of prostate is to produce part of the 
seminal fluid through which sperm is transported. Usually prostate cancer arises if the 
prostate cells fail to proliferate in an organized and controlled manner, which 
eventually leads to the formation of a prostate tumor (American Cancer 
Society,2013). As the outermost peripheral region of the prostate gland occupies the 
biggest area, a majority of prostate carcinomas were initially localized within this 
region. In addition, it is common for prostate cancer to originate from the epithelial 
cells of the glandular tissue to form adenocarcinoma and it is the most common form 
of prostate cancer. On the contrary, benign prostatic hyperplasia (BPH), a common 
benign form of prostate enlargement found in older men, tends to originate from the 
transition zone of the prostate gland (Timms, 2008).   
 As the disease progresses with the tumor growing bigger, there is a tendency 
for the tumor to grow through the prostate capsule and invade neighbouring tissues. 
Due to the rich network of blood and lymph vessels in the prostate gland, prostate 
cancer cells can also invade the vessels to metastasize to other sites of the body. More 
often than not, metastatic prostate cancer has a higher tendency to spread to the bones 
and lymph nodes. Once the disease progresses to metastatic prostate cancer, it will 
acquire a much more aggressive phenotype and it is usually associated with poor 
prognosis and with limited treatment options. 
3 
 
                                          
                         
Figure 1.1 Anatomy structure of prostate gland and the progression of Prostate 
Cancer 
 A. Anatomical structure of the prostate gland (Figure adapted from  
  http://www.cancer.gov/cancertopics/wyntk/prostate/page2) 
 B. Schematic showing the disease progression of prostate cancer (Figure 






1.1.1 Epidemiology of Prostate Cancer 
Prostate cancer is the most common cancer diagnosis and it is the second leading 
cause of cancer death after lung cancer in men. According to the latest cancer 
statistics published by The Amercian Cancer Society in 2013, it is estimated that 
238,590 new cases of prostate cancer will occur and with an estimated 29,720 death 
as a result of disease progression (American Cancer Society, 2013).  
 The only well-established risk factors for prostate cancer are increasing age, 
African ancestry, and a family history of the disease. Approximately 60% of all 
prostate cancer cases are diagnosed in men which are 65 years of age and older. 
African American men and Jamaican men of African descent have the highest 
reported prostate cancer incidence rate. It has been reported that the incidence rate of 
prostate cancer is approximately 70% higher in African-Americans population as 
compared to the Whites-Americans. However, the factors that predispose the African-
Americans to prostate cancer still remain elusive. 
 
1.1.2 The diagnosis of Prostate Cancer  
Long before the introduction of biomarkers which has revolutionized how oncologists 
diagnose and treat prostate cancer, prostatic acid phosphotase (PAP) was the first few 
clinical markers found to be elevated in the serum of men diagnosed with metastatic 
prostate in the 1930s (Lowe and Trauzzi, 1993). Ever since then, PAP has been 
intensively studied for its association with prostate cancer progression. However, in 
the 1980s, with the identification of elevated serum prostate specific antigen (PSA) 
levels as a first sign of abnormalities in the prostate gland, PAP was rapidly replaced 
by PSA to monitor the disease progression (Lilja et al., 2008). Ever since the 
widespread use of PSA as a screening marker to identify asymptomatic males who are 
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at risk of prostate cancer, PSA has revolutionized the diagnosis of prostate cancer in 
the past three decades. More importantly, prostate cancer death rates for both African 
American men and white men have been decreasing since the 1990s (American 
Cancer Society, 2013) as a result of detecting the disease in its early stages.  
 Patients with increased levels of PSA will usually undergo biopsy to detect the 
presence of any cancerous cells or abnormal histological features. From the biopsy 
results, the patients typically will be graded based on the Gleason scoring system 
which categorizes tumors from a scale of 1 to 5 (most to least differentiated) 
according to the most predominant architecture, and subsequently assigns a score that 
is the summation of the two most commonly observed patterns (Epstein, 2010). Upon 
the diagnosis of prostate cancer, the patients will be further classified according to the 
TNM staging system. The primary tumors can be categorized from T1 to T4, which 
T1 represents tumor that is localized within the prostate gland and T4 as a fully 
invasive tumor prostate tumor (Ohori et al., 1994).  
 
1.1.3 The treatment of Prostate Cancer 
The current treatment of prostate cancer largely depends on the stage of the cancer 
upon diagnosis. Prostate cancer patients will be further stratified based on the TNM 
staging criteria, PSA and Gleason score into high, intermediate and low risk groups 
which will determine the treatment options that are available to the patients (Figure 
1.2). Prostate cancer that are diagnosed in its early stages, are often treated locally 
with external radiation or prostatectomy and the initial responses to these treatments 
are often quite favourable. During the initial stages, prostate tumors are often 




Figure 1.2 Current strategies for the treatment of prostate cancer.  
When prostate cancer is initially diagnosed, the patient will usually undergo surgery 
or radiotherapy and it is usually curative if there is no further recurrence. However for 
approximately 30% of the patients, the disease recurs and the first-line therapy for 
recurring prostate cancer is androgen deprivation therapy (ADT). However, the 
disease will eventually develop resistance to ADT and progress to the more 
aggressive disease, castration-resistant prostate cancer (CRPC) which requires 
intervention with chemotherapy. PSA is a sensitive biomarker that reflects the disease 
burden of the prostate tumor. Schematic was extracted and modified from 
(www.essapharmaceuticals.com) 
 
Therefore, the first-line therapy for early prostate cancer is often androgen ablation by 
surgery or chemical castration (Chen et al., 2008; Walczak JR, 2007; Zhu et al., 
2010). Despite the general success of androgen deprivation therapy, the appearance of 
androgen-refractory is a negative outcome of the treatment with eventual fatal 
prognosis (Zhu et al., 2010). In such late-stage prostate carcinomas, treatment is often 
palliative with limited treatment options.  
 The metastatic prostate cancer is usually characterized by the formation of 
secondary tumors in the proximal and distal bone tissue which greatly affect the 
quality of life for CRPC patients as it is often accompanied by intense pain. Such 
patients would typically die within a year of such recurrence. Moreover, the treatment 
of CRPC patients is often delayed because the symptoms will only manifest several 
months later. At this stage, CRPC patients are left with limited treatment options apart 
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from chemotherapy. Moreover, Cytotoxic drugs such as Docetaxel can only extend 
the lifespan of CRPC patients by an average of four months. 
 Despite the emergence of new second line therapies such as immunotherapy 
(Lee, 2002), COX2 inhibition (Cai et al., 2008), inhibition of neo-angiogenesis 
(Sternberg, 2003) and gene vaccination therapy (Gulley et al., 2002) which display 
anti cancer effects in vitro and could reduce PSA levels in vivo, none of these 
treatments could significantly increase disease free survival with advanced prostate 
cancer. Moreover, when these second-line therapies fail, patients will typically die 
within a few months. Hence, there is a pressing need to develop new therapeutic 
strategies to improve the survival rate and the quality of life of CRPC patients.  
 
1.1.4 Common molecular aberrations in Prostate Cancer 
 
 
Figure 1.3 Common molecular aberrations that occur during human prostate 
cancer progression. 
Stages of progression are shown, together with molecular processes and 
genes/pathways that are likely to be significant at each stage. Diagram is extracted 
and modified from (Shen and Abate-Shen, 2010)  
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1.1.4.1 Over-expression of MYC oncogene in Prostate Cancer 
The MYC gene was first identified as an avian viral oncogene that causes 
myelocytomatosis in birds in the late 1970s (Sheiness and Bishop, 1979). To date, 
three forms of MYC protein (c-MYC, N-MYC, and L-MYC) has been identified in 
human and they share the same topography with their coding region located within 
the second and third exons. The MYC protein adopts a basic Helix-Loop-Helix 
Leucine Zipper structure that heterodimerizes with its small protein partner, Max to 
bind at regions with the consensus sequence (CACGTG) or similar E-box sequences 
(Albihn et al., 2010). Out of the three forms of MYC protein, c-MYC is one of the 
most extensively studied. The c-MYC protein is a transcription factor that regulates a 
diverse range of cellular processes such as cell growth and proliferation, cell-cycle 
progression, stem cell renewal and differentiation, apoptosis and cellular motility 
(Albihn et al., 2010). As opposed to normal cells which only express the gene when 
the cells are actively divide; c-MYC expression is often de-regulated in cancer cells as 
a result of genetic aberrations. Indeed, c-MYC is overexpressed in wide variety of 
human cancers with 80% of breast cancers, 70% of colon cancer, 50% of 
hepatoceullar carcinomas and several hematological tumors harboring abnormal 
MYC. (Spencer and Groudine, 1991).  
 Likewise in prostate cancer, the level of amplification of c-myc gene at 
chromosome 8q24 was found to increase as the disease progresses from the benign 
prostatic intra-epithelial neoplasia (PIN) through localized prostate tumors to the 
metastatic disease (Gurel et al., 2008; Jenkins et al., 1997; Sato et al., 1999). It was 
previously reported by Sato et al, that the amplification of c-MYC was positively 
correlated to higher histopathological grades, Gleason Score and poor prognosis (Sato 
et al., 2006).  Consistently, Jenkins et al has reported that the gain in copy number of 
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chromosome 8 was common in PIN, adenocarcinomas and distant metastases. 
However, the amplification of the MYC gene itself was largely observed in metastatic 
prostate cancer. In agreement with Jenkin’s study, the amplification of c-myc was also 
reported at a frequency of 29% in 37 hormone refractory recurrent prostate carcinoma 
despite observing gains of chromosome 8 in 72% of the cases (Nupponen et al., 
1998). 
 The over-expression of MYC often predicts poor prognosis associated with 
progression to mestastasis (Wolfer et al., 2010). Its over-expression is frequently 
associated with an increase risk of biochemical recurrence of prostate cancer 
(Hawksworth et al., 2010). The key function of c-MYC in prostate cancer metastatic 
progression has been well demonstrated in a transgenic mice model which over-
expressed human c-MYC in the prostate. The prostate specific over-expression of c-
MYC has led to the formation of localized prostate adenocarcinoma which progressed 
to acquire invasiveness and formed metastatic lesions. These murine lesions shared 
many molecular similarities with human prostate tumors and expressed high level of 
MYC (Ellwood-Yen et al., 2003). Their data has demonstrated that MYC over-
expression could drive neoplastic transformation and supported the notion that MYC 
was implicated in the initiation and progression of human prostate cancer. Likewise, 
retroviral overexpression of c-MYC can also immortalize normal primary prostate 
epithelial cells and renders prostate cancer cell growth independent of androgen. In 
agreement with the in vitro and in vivo studies, there was a significant increase of c-
MYC amplification in advanced prostate tumors after receiving androgen deprivation 
therapy (Kaltz-Wittmer et al., 2000). Collectively, it is indisputable that c-MYC plays 
an important role in advanced prostate cancer and is implicated in progression of 
prostate cancer. However, the mechanism underlying MYC’s oncogenic function in 
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prostate cancer remains elusive and more studies is warranted to better understand the 
molecular events that occurs as a result of MYC overexpression during the 
development of prostate cancer.    
 
1.1.4.2 Aberrant PI3K signaling in prostate cancer 
The activation of the PI3K/AKT/mTOR signaling pathway is another pathway that 
has been strongly implicated in the progression of prostate cancer (Pourmand et al., 
2007; Taylor et al., 2010). Similar to MYC, the PI3K/AKT/mTOR signaling pathway 
is responsible for a wide variety of cellular functions, which includes cell growth and 
proliferation, invasion and migration, angiogenesis and stem cell renewal and 
differentiation(Courtney et al., 2010; Dubrovska et al., 2009; Furic et al., 2010; Hsieh 
et al., 2012). There are three categories of PI3K that differ by their substrate 
specificities and the class 1A PI3Ks are the most frequently implicated in prostate 
cancer (Bitting and Armstrong, 2013). The class 1A PI3K consists of a catalytic 
subunit p110 and a regulatory subunit p85 (Courtney et al., 2010).  
 Upon activation of the PI3K signaling, phosphatidyl inositol 4,5- bisphosphate 
(PI(4,5)P2 will be phosphorylated by activated PI3K to phosphatidyl inositol 3,4,5- 
triphosphate (PI(3,4,5)P3. This will in turn recruit Akt protein to the cell membrane 
where it is fully activated through the phosphorylation by mTOR complex 2 (TORC2) 
at S473 and T308 (Bitting and Armstrong, 2013; Courtney et al., 2010). Upon Akt 
activation, it phosphorylates a myriad of other transcription factors such as FOXO 
proteins, glycogen synthetase 3 (GSK3) and tuberous sclerosis complex (TSC) to 
initiate the transcriptional expression of their target genes (Liu et al., 2009). As the 
PI3K signaling pathway is important for regulating cell proliferation and survival, 
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precise regulation on its activity is crucial for the prevention of cancer development. 
The tumor suppressor, phosphatases and tensin homolog (PTEN) is one of the 
negative regulators of the PI3K/AKT/mTOR signaling pathway, which converts 
PI(3,4,5)P3 to PI(3,4)P2 to inhibit PI3K activity (Liu et al., 2009).  
 In prostate cancer, aberrations of various component of the PI3K/AKT/mTOR 
signaling pathway have been reported in 42% of primary prostate tumors and all of 
the metastatic tumors. Some of the more common genetic alterations include PTEN 
deletion, constitutive mutation of PI3K and copy number alterations (Taylor et al., 
2010). These aberrations in prostate tumors lead to a constitutive increase in 
PI3K/AKT/mTOR, conferring cancer cells proliferative and survival advantages. In 
addition, the loss of PTEN and constitutive AKT activation has been correlated to 
poor clinical prognosis, biochemical recurrence and resistance to chemotherapy 
(Ayala et al., 2004; Kreisberg et al., 2004; Qian et al., 2010). Similarly, conditional 
deletion of Pten in the murine prostate, recapitulates the disease progression in human 
prostate cancer, from prostatic intraepithelial neoplasia (PIN) to invasive 
adenocarcinoma and subsequently to metastatic prostate cancer with similar kinetics 
(Wang et al., 2003). More recently, constitutive activation of PI3K/AKT signaling 
due to loss of PTEN has also been associated with increased risk to progress to 
metastatic prostate cancer within a shorter time frame (Lotan et al., 2011). Mulholland 
et al has further demonstrated that the loss of PTEN is implicated in the development 
of late stage castration-resistant prostate cancer (CRPC) by suppressing the androgen 






1.1.4.3 Aberrant androgen receptor signaling in MYC amplified and 
hyper-activation of PI3K signaling  
The androgen receptor (AR) is a phosphoprotein that mediates the functions of 
dihydrotestosterone (DHT) and testosterone by acting as a transcription factor. It is 
required for the proper proliferation of prostate epithelial cells and to suppress 
apoptotic death. Androgen binds and activates the AR, which stimulates it to bind to 
androgen responsive elements (AREs) which are present in the promoters of 
Androgen stimulated genes. The interaction between the AR and the AREs of its 
target genes could be influence by a myriad of other transcription regulators.  
 As the proliferation of prostate cancer cells largely depends on the level of 
androgens, androgen deprivation treatment (ADT) has been the first-line treatment for 
advanced prostate cancer. Despite initial response to ADT was effective in slowing 
the progression of the disease, most patients will eventually relapse. The change in 
androgen-refractory growth is likely due to the evolutionary selection of a minority of 
prostate cancer cells that are unresponsive to androgen and the ADT confers selective 
advantages to the cancer cells. Although the CRPC cells are resistant to ADT, they 
often continue to express high levels of AR and androgen regulated genes such as 
PSA before and after androgen ablation treatment. In agreement with the role of AR 
in driving castration resistant prostate cancer, AR was found to be rarely amplified in 
primary prostate cancer and it is amplified in 22%-30% of androgen refractory 
cancers. In another study that involved the fluorescence in situ hybridization of 371 
tumor samples, reported that AR was amplified in 22% of metastatic prostate cancer 
and in 23% of the local recurrent androgen-refractory cancers.    
Interaction of AR signaling with oncogenic pathways also plays a role in ligand-
independent activation of AR. Loss of PTEN function and deregulation of PI3K/AKT 
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signaling, is one of the most common aberrations detected in prostate cancers. 
However, the interaction between the PTEN/PI3K/AKT pathway and AR signaling 
and its role in CRPC development remain elusive. Results of two independent studies, 
using conditional PTEN-knockout mouse models of prostate cancer, have showed that 
PTEN deletion can reduce AR expression by differing mechanisms. Studies by Carver 
and colleagues have demonstrated that the loss of PTEN and subsequent activation of 
HER kinase can decrease AR activity (Carver et al., 2011). On the contrary, using 
genetically engineered mouse models harboring conditional PTEN and AR knockouts, 
Mulholland and colleagues showed that AR function is not a prerequisite for the 
development of prostate cancer (Mulholland et al., 2011). It was shown that loss of 
PTEN inhibited the expression and activity of a number of proteins involved in 
modulating AR activity and repressed AR activity. Together, the data suggest that 
PTEN loss and AKT activation can suppress AR signaling, and the development of 
prostate cancer can occur in the absence of robust AR signaling. 
Apart from the cross-talk between AR and PTEN/PI3K/AKT signaling pathway, 
deregulation of certain genes and molecular pathways has been associated with 
prostate cancer progression, including activation of PI3K–AKT–mTOR and RAF–
MEK–ERK–MAPK pathways and increased expression of MYC. However, the 
mechanism by which MYC is activated and its interaction with other signaling 
pathways remain elusive too. A previous study has demonstrated that upregulation of 
c-Myc cooperated with the activation of PI3K–AKT–mTOR and MAPK signaling 
pathways, in which conditional loss-of-function of PTEN was combined with the 
activation of oncogenic Braf (Wang et al., 2012). Accordingly, therapeutic treatments 
targeting these pathways reduced c-Myc levels and suppressed tumor and metastatic 
progression in the same system. It was suggested that the activation of Myc pathway 
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is an important consequence of activation of PI3K–AKT–mTOR and MAPK 
signaling in CRPC. Hence, these findings provide novel insights into study Myc and 
its related signaling pathways as targets for therapeutic intervention in CRPC. 
 
1.1.5 Major challenges in Prostate Cancer treatment   
Unlike many other human cancers which have relatively well defined 
histopathological subtypes for clinicians to diagnose and decide the appropriate 
treatment, prostate cancer is a heterogeneous disease with few distinct 
histopathological subtypes. Currently, its diagnosis and prognosis are still heavily 
reliant on the differentiation status of the prostate tumors as represented by the 
Gleason Score (Epstein, 2010). Recently, the usage of PSA as a diagnostic marker for 
prostate cancer has sparked heated debate within the medical community due to its 
high false positive rates. Although, PSA has led to the earlier detection of prostate 
tumors before they progresses to the malignant stage, serum PSA can also be elevated 
due to many other instances, such as prostate enlargement, inflammation of the 
prostate and benign growth in the prostate etc (Shen and Abate-Shen, 2010). This is 
particularly a concern because a significant proportion of the low-grade prostate 
tumors will remain relatively indolent for a long period of time, with a small fraction 
of prostate tumors that will progress to acquire an aggressive phenotype that require 
active intervention (Shen and Abate-Shen, 2010). As a result, the adverse effects of 
treatment, both financially and physically to the patients are becoming a worrying 
concern over the issue of overtreatment in patients with the indolent disease. Hence, 
there is a pressing need for the development of novel biomarkers that could more 
accurately stratify prostate tumors for appropriate treatment according to their 
prognosis and aggressiveness.       
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 Clinical heterogeneity in prostate cancer is not the only major challenge that 
most clinicians are facing. A significant proportion of patients will relapse after 
surgical or chemical castration and require further intervention. For years, the first 
line therapy for relapse cases revolves around the principle of interfering of the 
androgen signaling by inhibiting the androgen receptor (AR) activity. In the initial 
stages, almost all tumours will respond favourbly to the androgen deprivation 
therapies. However, a significant proportion of the prostate tumors will progress by 
developing resistance to androgen deprivation treatment to become the highly lethal 
CRPC whereby treatment options are currently limited (Wyatt et al., 2013). 
Therefore, it is imperative to understand the molecular events induced by oncogenic 
















1.2.1 Introduction to role of epigenetics and chromatin modification 
in cancer 
Epigenetics is often defined as the study of somatically heritable alterations in the 
genetic expression that are not due to changes in the primary DNA sequence. A 
myriad of biological properties can be influenced by epigenetic mechanisms and such 
epigenetic regulations are pivotal for the development and differentiation of various 
cell types and X-chromosome inactivation in females (Baylin and Jones, 2011). 
However when the precise balance of epigenetic regulations are disrupted due to 
environmental influences or during ageing, it can contribute to the development of 
cancer and many other diseases. 
Epigenetic processes involve chemical modifications either to DNA or to the histone 
proteins that strands of DNA wound to form the nucleosomes (Jones and Baylin, 
2002). In addition, epigenetic regulators also define the architecture of gene 
expression states by regulating the chromatin structure. Nucleosome positions are 
often dynamic in nature and change during cell replication and genetic expression. 
Alterations to chromatin states by epigenetic regulators can affect the accessibility of 
transcription factors to the target DNA to initiate gene transcription (Jones and 
Baylin, 2007). Apart from DNA methylation, other epigenetic processes such as 
histone ubiquitination, histone deacetylation, and chromosome remodeling can also 
contribute to oncogenesis when their activities are dys-regulated. For instance, the 
PRC2 complex was found to physically interact with Histone Deacetylase (HDAC) 
and recruit HDACs to their target genes (Simon and Lange, 2008). Histone tails are 
usually positively charged due to high composition of arginines and lysines. On the 
contrary, DNA is highly negative charged due to the phosphor groups from the 
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phosphor-diester backbone. Consequently, when the negatively charged DNA is 
wound around the positively charged histones, the strong ionic bonding between them 
would lead to the compaction of the chromatin and reduces the accessibility of target 
gene promoters to transcription factors.  
Chromosome remodeling is another important epigenetic mechanism that is also often 
implicated in the development of cancer. Chromatin re-modifying proteins serve to 
regulate the positioning of nucleosome and subsequent transcriptional event. In 
cancers, it has been reported that SWI/SNF, a family of chromatin remodeling 
complexes was frequently mutated or inactivated. This observation was found to be 
correlated with the repression of tumor suppressor genes such as the INK4A (Kia et 
al., 2008). It was found that the occupancy of PcG proteins could block the 
recruitment of SWI/SNF (Wilson et al., 2010). The antagonism between SWI/SNF 
and EZH2 was further demonstrated that the loss of SNF5 could lead to elevated 
expression of EZH2 and the in vivo tumorigenicity induced by SNF5 knockout could 
be rescued by EZH2 knockout (Wilson et al., 2010). 
1.2.2 Molecular biology of PRC complexes and EZH2 
During cellular development, the fate of a cell is tightly regulated by the precise 
expression of genes that determines its function. After the cell has acquired its 
identity, this cellular identity has to be maintained by switching “on” some genes and 
“off” for other genes. If the maintenance mechanism fails, cells may lose their ability 
to proliferate and differentiate in an orderly and organized fashion (Margueron and 
Reinberg, 2011). Cancer often arises from the accumulation of such cellular defects 
over time. The precise spatial and temporal regulation of these developmental genes 
can be greatly exerted at numerous levels, one of which is the accessibility of genes to 
components of the transcriptional machinery. Hence, this would determine whether 
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the genes are kept in the “on” or “off” state (Schuettengruber and Cavalli, 2009) and 
gene accessibility can be largely influenced by the degree of local chromatin 
compactness. The local chromatin structure can be largely influenced by post-
translation modification to the histone tails and DNA methylation.  
 The Polycomb Group (PcG) is one such factor that have been identified to 
influence the chromatin structure by post-translational modification of histone tails, 
leading to the enhancement or repression of transcription. The PcG genes were 
originally identified in Drosophila more than three decades ago, as regulators of body 
development by repressing Hox genes and have since then been regarded as important 
epigenetic transcriptional repressors in deciding cell fate and differentiation (Schwartz 
and Pirrotta, 2007). The PcG proteins are able to assemble into chromatin remodeling 
complexes and are broadly catergorized into Polycomb repressive complex 1 (PRC1) 
and 2 (PRC2) in mammals (Simon and Kingston, 2009). Although, the components of 
these complexes may varies across different species, but their core subunits are highly 
conserved from Drosophila to humans (Whitcomb et al., 2007).  
 The PRC1 complex comprises of the RING1, CBX2, PHC, BMI1 subunits 
(Figure 1.4, Left) which are responsible for facilitating the monoubiquitination of 
Lysine 119 of histone H2A (H2AK119ub) via E3 ubiquitin ligases RING1A/B 
(Simon and Kingston, 2009). The chromobox homolog 2 (CBX2) subunit recognizes 
and binds to tri-methylated H3K27 sites, allowing the PRC1 complex to catalyze the 
H2AK119 monoubiquitination process only at specific genes that are required to be 
silenced (Simon and Kingston, 2009). PRC1 complex has been found to inhibit the 
ATP dependent remodeling of Swi/Snf in vitro (Shao et al., 1999) and is able to cause 
chromatin condensation in the absence of histone tails (Francis et al., 2004). 
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 On the other hand, the PRC2 complex comprises of suppressor of Zeste 12 
(SUZ12), embryonic ectoderm development (EED), retinoblastoma suppressor 
protein 46/48 (RbAp46/48), and its catalytic core-subunit, enhancer of zeste 
homologue 2 (EZH2) (Figure 1.4, Right). EZH2 possesses histone methyltransferase 
activity within its SET domain as it provides the active site for covalent methylation 
reaction to catalyze the trimethylation of histone H3 (H3K27me2 or me3) and H3K9 
to a lesser extent (Cao et al., 2002; Kirmizis et al., 2004; Schuettengruber et al., 
2007). H3K27me3 restricts access of other transcriptional activating factors, resulting 
in gene repression independent of the promoter. Similarly, H3K27me3 also serves as 
an anchorage point for the recruitment of other Polycomb proteins which facilitates 
the condensation of the chromatin resulting in gene silencing. Interestingly, EZH2 
subunit alone lacks intrinsic histone methyltransferase activity, and it requires the 
interaction with at least two other non-catalytic components, EED and SUZ12 to be 
catalytically active (Rea et al., 2000). In addition, the PRC2 complex can also exist in 
another form by complexing with EZH1, a closely related member of EZH2. It has 
been found that EZH1 is expressed in both dividing and differentiated cells, whereas 
EZH2 is exclusively found in actively dividing cells (Margueron et al., 2008). In 
addition, PRC2 complex that consist of EZH1 has been reported to have a lower level 
of methyltransferase activity as compared to PRC2 complex that consist of EZH2 
(Margueron et al., 2008). These observations suggest that the PRC2-EZH2 complex is 
responsible for establishing de novo cellular H3K27 di or tri-methylation and PRC2-








               
 
Figure 1.4 PRC1 and PRC2 complex formed by various polycomb protein 
components.  
Schematics representing the composition of PRC1 and PRC2 as shown, are extracted 
and modified from (Margueron and Reinberg, 2011). The classical PRC1 complexes 
are represented on the left and the canonical PRC2 complex along with its accessory 
proteins are represented on the right. (Left) PRC1 complex. Due to their homology 
with the Drosophila PSC protein, BMI1-, MEL18- and NSPC1-containing PRC1 
complexes could compact chromatin by interacting with the CBX proteins that 
specifically recognizes H3K9/27me3 at its chromodomain. HPH1, 2 and 3 denote 
human polyhomeotic homologue 1, 2 and 3. (Right) PRC2 complex. EZH1/2, EED, 
SUZ12 and RbAp46/48 are the core components of the PRC2 complex. EZH1/2 is the 
catalytic component of the PRC2 complex which is responsible for its histone 
methyltransferase activity at its SET domain. Recent studies have shown that PRC2 
possesses several other accessory proteins such as AEBP2, PCLs and JARID2 which 
could regulate the activity of EZH2. 
 
1.2.3 Role of EZH2 in human cancers 
The expression of EZH2 and its PRC2 components are found to be frequently de-
regulated in wide variety of cancers, including advanced and high-grade prostate, 
breast and lung cancer, melanoma and lymphoma (Kleer et al., 2003; McHugh et al., 
2007; Varambally et al., 2002; Yan et al., 2013). EZH2 has also been reported as a 
predictive marker of aggressiveness and its high expression is often associated with 
poor prognosis and survival in both prostate and breast cancer (Kleer et al., 2003; 
PRC 1 PRC 2 
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Varambally et al., 2002). In addition, EZH2 is overexpressed in more than half of the 
castration resistant prostate cancer and the overexpression were more frequently 
observed in late stage prostate cancer highlighting its role in tumor progression 
(Saramaki et al., 2006). 
 The oncogenic role of EZH2 was also well demonstrated in vitro studies 
which ectopic overexpression of EZH2 was able to result in oncogenic transformation 
of benign prostatic and breast epithelial cells (Karanikolas et al., 2009; Li et al., 
2009). Ectopic overexpression of EZH2 in cancer cell lines that were weakly invasive 
resulted in increased motility and invasiveness of cancer cells, further indicates that 
EZH2 is implicated in promoting cancer progression to acquire a more aggressive and 
invasive phenotype (Collett, 2006; Varambally et al., 2002). On the contrary, 
depletion of EZH2 inhibits proliferation and tumor formation in vivo (Gonzalez et al., 
2009; Varambally et al., 2002). 
 Apart from the frequent deregulated expression of EZH2 observed in many 
cancers, somatic mutations and deletions of EZH2 have been identified to disrupt 
EZH2 functions in recent years. Most of the somatic mutations reported were found in 
hematologic malignancies such as 30% of germinal center diffuse large B cell 
lymphomas (DLBCL), 10% of follicular lymphomas and patients with 
myeloproliferative disorder (Ernst et al., 2010; Morin et al., 2010; Nikoloski et al., 
2010). One of the first somatic mutations of EZH2 was discovered in the catalytic Set 
domain of EZH2 at residue Y641 and was perceived to inactivate the 
methyltransferase activity of EZH2 in lymphomas (Morin et al., 2010). Although the 
disease associated Tyr 641 mutated EZH2 has very limited capability to mono-
methylate H3K27, the mutant possesses much higher efficiency to convert di-
methylated H3K27 to tri-methylated H3K27 as compared to the WT EZH2. As the 
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mutant allele is more commonly found to be heterozygous in disease cells, the authors 
hypothesized that the malignant disease may require the coordinated activities 
between the WT EZH2 to monomethylate H3K27 before the Tyr 641 mutant EZH2 
could efficiently perform the trimethylation reaction on H3K27 (Morin et al., 2010). 
Consistently in another independent study, Yap et al. has demonstrated that the Tyr 
641 EZH2 mutant binds with a lower affinity for unmethylated and monomethylated 
H3K27 substrate but higher affinity for di-methylated substrate to be tri-methylated 
possibly due to the substitution of the tyrosine residue to a structurally neutral 
Phenylalanine (Yap et al., 2011).  
 On the contrary, inactivating mutations of EZH2 has also been reported in 
myeloid neoplasia, which EZH2 is found to be affected by deletions and nonsense 
mutations that causes its loss of function (Ernst et al., 2010). These inactivating 
mutations could result in premature termination of its transcription or direct 
impairment of its methyltransferase activity, suggesting that EZH2 may play a tumor 
suppressive role in these myeloid neoplasia. The presence of both activating and 
inactivating mutations of EZH2 in different cancers, strongly suggest that EZH2 
function as part of the PRC2 complex maybe highly context-dependent. It is still 
unclear how EZH2 could regulate different set genes or mediate different epigenetic 
programs in different cancers and thus, further efforts to elucidate the context 
dependent role of EZH2 in different context and cancer is warranted.      
  
1.2.4 Regulation of EZH2 expression in cancer 
EZH2 has been reported to be frequently overexpressed in multiple human cancers as 
described in previous sections. The expression of EZH2 appears to be tightly 
regulated at both the transcriptional and post-transcriptional level. In this section, 
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emphasis will be placed on various underlying mechanisms leading to the 
overexpression of EZH2 in cancer.  
 
1.2.4.1 Transcriptional regulation of EZH2 in cancer 
At the transcriptional level, EZH2 was found to be regulated by several well 
established transcription factors that are implicated in cancer. The E2F family of 
transcription factors is among the first to be reported to regulate the transcriptional 
expression of EZH2. E2F is a target of the retinoblastoma protein (pRB) and it plays a 
crucial role in regulating genes that control the cell cycle progression (Ren et al., 
2002). In the unphosphorylated state of Rb, it binds and sequesters E2F and inhibits 
the expression of its target genes. Upon phosphorylation of Rb, E2F is released from 
inhibition and could bind to the promoter of EZH2 and activate the transcription of 
EZH2 (Muller et al., 2001). Indeed Bracken et al have demonstrated that EZH2 lies 
downstream of the tightly regulated pRB-E2F pathway and de-regulation of this 
pathway has led to the overexpression of EZH2 and conferred proliferative advantage 
to cancer cells (Bracken et al., 2003).   
 Notably, it has been previously shown in our lab that E2F1 could induce the 
transcriptional expression of EZH2 and inhibits E2F1 induced cell death by repressing 
the expression of Bim, therefore conferring survival advantages to cancer cells (Wu et 
al., 2010). Functionally, it has been demonstrated that VEGF induced activation of 
E2F1 and E2F3 could lead to an increase in endothelial EZH2 resulting in the 
H3K27me3 mediated silencing of vasohibin 1 (Vash1), which is an inhibitor of tumor 
angiogenesis (Lu et al., 2010a). Similarly, EZH2 expression can also be regulated by 
hypoxia inducible factors under hypoxic conditions. In the hypoxic tumor 
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microenvironment, EZH2 expression can be induced by HIF response element (HRE) 
in the promoter of EZH2 to drive the proliferation of cancer cells (Chang et al., 2011).  
 In another independent study, EZH2 has been reported to be a direct target of 
Elk which is downstream of the Ras/MAPK/ERK pathway in ERRB2 overexpressing 
breast cancer cell lines (Fujii et al., 2011). Lastly, the p53 tumor suppressor was also 
found to be a negative regulator of EZH2 transcriptional expression (Tang et al., 
2004). Importantly, more than 50% of human cancer harbor either loss-of-function 
mutations or downregulation of p53 expression which could alleviate the repression 
on EZH2 to be overexpressed in these cancers with impaired p53 signaling.   
 
1.2.4.2 Post-transcriptional regulation of EZH2: MicroRNAs  
MicroRNAs (miRNAs) are a family of small non-coding RNAs consisting of 20–22 
nucleotides, which are usually excised from 60–110 nucleotide precursor RNA 
structures (Calin and Croce, 2006). Functionally, miRNAs could regulate the 
expression of their target genes by binding to imperfect complementary sites within 
the 3′ untranslated regions (UTRs) of their mRNA targets. This binding would 
subsequently lead to either target degradation or the translational repression on the 
target gene expression (Esquela-Kerscher and Slack, 2006; Lim et al., 2005). In recent 
years, small non coding micro RNAs (miRNAs) have been recognized as important 
regulators of many cellular pathways and have been reported to be de-regulated in 
many cancers. Several miRNAs such as miR-26a, miR-101 and miR-214 have been 
identified to bind to the mRNA transcripts of EZH2 and inhibit their expression.  
 MiR-101 was the first microRNA identified to inhibit the expression of EZH2 
by targeting the 3’UTR of EZH2 mRNA to promote its degradation (Varambally et 
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al., 2008). Approximately 40% of the localized prostate cancer and 66% of the 
metastatic prostate cancer has lost at least one or both alleles of the miR-101 gene. In 
the same study, overexpression of miR-101 could inhibit cell proliferation and 
invasiveness of cancer cells which mimics the effect of knocking down the expression 
of EZH2 in these cells (Varambally et al., 2008). Interestingly, EZH2 was also found 
to be a target of miR-26a and the overexpression of MYC decreases miR-26a 
expression and promotes tumorigenesis by allowing the expression of EZH2 in 
prostate cancer and lymphomas. (Borno et al., 2012; Koh et al., 2011; Sander et al., 
2008).  Apart from the relatively well studied miR-101 and miR-26a, emerging 
evidence has suggested that miR-214 which was initially found to regulate EZH2 in 
skeletal muscle and embryonic stem cells (Juan et al., 2009) does negatively regulate 






      
Figure 1.5 EZH2 signaling and its involvement in different cell signaling 
pathways and tumorigenesis.  
The expression of EZH2 is tightly regulated by multiple factors and they are often de-
regulated during the progression of cancer. EZH2 can be regulated by miRNAs such 
as miR-101 and miR-26a, tumor suppressors such as p53, RB and BRCA1 as well as 
Myc and PI3K/AKT signaling pathways. By mediating the repression of its target 
genes (shaded brown), EZH2 is involved in the regulation of various important cell 
signaling pathways like the Wnt/β-Catenin signaling, Ras signaling and β- adrenergic 
signaling. De-regulation of EZH2 expression which often occurs during cancer 
progression, leads to uncontrolled growth and survival signals and promotes cancer 
cell invasion in late stage tumors.      
 
1.2.4.3 Post-translational regulation of EZH2 
Prior to the discovery that EZH2 activity can be regulated by post translational 
modification, most of the focus in the scientific community was on the overexpression 
of EZH2 observed in human cancers. Pioneering work by M.C Hung and colleagues 
have demonstrated that EZH2 could be post-translational modified by AKT mediated 
serine phosphorylation (Cha et al., 2005). The study revealed that activated AKT 
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could phosphorylate EZH2 at Serine 21, which in turn would reduce the binding 
affinity of EZH2 to H3K27 substrates and subsequently decrease H3K27me3 leading 
to de-repression of its silenced genes. In addition, high level of MYC has been 
reported to inhibit PI3K/AKT signaling activation via PTEN tumor suppressor leading 
to a decrease in Serine 21 phosphorylation, and therefore an increase in EZH2 activity 
(Kaur and Cole, 2013).   
 Similarly, an earlier study  by Wei and colleagues also revealed an alternative 
phosphorylation site of EZH2 at Threonine 487 and is subjected to regulation by 
cyclin-dependent kinase 1 (CDK1), a key player of cell cycle regulation (Wei et al., 
2011). It was found that T487 phosphorylation resulted in the dissociation of EZH2 
from PRC2 complex and led to a corresponding decrease in H3K27me3. 
Consequently, this led to the de-repression of EZH2 target genes that negatively 
regulates cancer cell migration and osteogenic differentiation of mesenchymal stem 
cells. On the contrary, the first phosphorylation site that could increase EZH2 histone 
methyltransferase activity was identified by Chen and colleagues (Chen et al., 2010). 
It was discovered that CDK1 and CDK2 works cooperatively to phosphorylate EZH2 
at Threonine 350 (Chen et al., 2010). In contrast to both S21 and T487 
phosphorylation which are inhibitory, T350 phosphorylation increases the recruitment 
of EZH2 to its target genes to maintain the H3K27me3 levels. In addition, inhibition 
of T350 phosphorylation abrogated the global effect of EZH2 mediated gene silencing 
and inhibited EZH2 mediated cell migration and proliferation (Chen et al., 2010). 
  
1.2.4.4 Regulation of EZH2 activity by co-factors 
Apart from post-translational modification on EZH2, the H3K27me3 levels can also 
be regulated by interacting factors which direct the binding of PRC2 complex to its 
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target genes. Recently, JARID2 is one of such interacting partner of PRC2 complex 
that was identified and it has been shown to direct the recruitment of PRC2 core 
components specifically to their target genes in embryonic stem cells. (Pasini et al., 
2010). More importantly, the inhibition of JARID2 expression inhibited PRC2 
binding resulting in a concurrent loss of H3K27me3 on its target genes, suggesting 
that JARID2 is crucial for the recruitment of PRC2 core components to its target 
genes. On the contrary, a negative modulator of the PRC2 complex was recently 
unraveled by Wang and colleagues. It was found that the tumor suppressor protein, 
breast cancer susceptibility gene 1 (BRCA1) interact with EZH2 and inhibits the 
binding of EZH2 to its target genes in both mouse embryonic stem cells and breast 
cancer cells (Wang et al., 2013). Phenotypically, the decrease in BRCA1 expression 
blocks ES cell differentiation and enhances the ability of the breast cancer cells to 
migrate and invade in an EZH2-dependent fashion (Wang et al., 2013).  
 More recently, Lewis et al have reported that the lysine to methionine (K to 
M) mutation at residue K27 in histone 3 (H3) could inhibit PRC2 methyltransferase 
activity by targeting active sites of various SET domain-containing 
methyltransferases, particularly EZH2 (Lewis et al., 2013). They have shown that 
through competing with substrate binding and turnover, the H3K27M mutants could 
reduce the global H3K27me3 levels in human diffuse intrinsic pontine gliomas 
tumors. This is the first landmark study that has demonstrated the methyltransferase 
activity of EZH2 can be regulated and inhibited by mutant substrates to alter 




1.2.5 Non-Canonical roles of EZH2: H3K27me3 independent 
functions 
Apart from EZH2 canonical role as a transcriptional repressor through H3K27me3 
gene silencing of its target genes, there is accumulating evidence to suggest that the 
oncogenic functions of EZH2 may not solely dependent on its H3K27me3 mediated 
gene silencing activity. Emerging evidence from other histone methyltransferases 
such as SET7/9 can regulate key signaling pathways by directly methylating p53 
(Huang et al., 2006), NF-kB (Lu et al., 2010b) and STAT3 (Yang et al., 2010) which 
have raised the possibility that EZH2 could have such functions too. Indeed, Kim et al 
has recently demonstrated that phosphorylation of EZH2 by AKT could activate 
STAT3 signaling by methylating STAT3 to promote tumorigenicity of Giloblastoma 
Stem Cells (GSCs).    
 A recent landmark study by Xu and colleagues has revealed that EZH2 in 
castration resistant prostate cancer (CRPC) also function as a transcriptional activator 
which induces the expression of a specific subset of its target genes (Xu et al., 2012). 
However, this functional switch from its traditional role as a repressor to a co-
activator of androgen receptor (AR) requires an intact histone methyltransferase 
domain and S21 phosphorylation status of EZH2. Likewise, a previous study in our 
lab has further exemplified how EZH2 can switch from a repressor role to an activator 
role depending on the context and molecular subtype of the breast cancer (Lee et al., 
2011). In ER
+ 
luminal breast cancer cells, EZH2 interacts with ER and directly 
inhibits NF-kB target gene expression through repressive histone methylation on their 
promoters. On the contrary, in ER
-
 basal-like breast cancer cells that lack the 
expression of ER, EZH2 forms ternary complex with NF-κB subunits RelA and RelB 
to activate NF-kB target gene expression. In addition, the oncogenic role of EZH2 in 
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natural killer / T-cell lymphoma (NKTL) was recently reported to be independent of 
its methyltransferase activity too. The authors have demonstrated that ectopic 
expression of EZH2 mutant that lacks the histone methyltransferase activity could still 
confer growth advantage and rescue the inhibition on proliferation due to EZH2 
depletion in NKTL cells (Yan et al., 2013). Subsequently, it was found that the mutant 
EZH2 could directly drive the transcription of Cyclin D1, an important cell cycle 
regulator, in the absence of its enzymatic activity.     
 Interestingly, accumulating evidence has shown that EZH2 can methylate non-
histone proteins too. A recent report by He and colleagues have revealed that the 
transcription factor GATA4’s transcriptional activity can be regulated by EZH2 
mediated methylation (He et al., 2012). It was demonstrated that the EZH2 mediated 
methylation of GATA4 could greatly reduce its interaction with and acetylation by 
p300 to inhibit its transcriptional activity. Likewise, Kim et al have recently showed 
that EZH2 could bind and methylates STAT3 in Giloblastoma stem cells, leading to 
enhanced STAT3 activation by increased tyrosine phosphorylation of STAT3 (Kim et 
al., 2013). In addition, EZH2 can also influence the protein stability of non-histone 
proteins by “tagging” them for degradation via its methyltransferase activity. It has 
been reported that the CUL4 E3 ubiquitin ligase complex and a DDB1/cullin4 
(CUL4) associated factor 1 (DCAF1) adaptor can specifically recognize non-histone 
substrates that has been mono-methylated by EZH2 (Lee et al., 2012). Hence, though 
EZH2 mediated methylation, these non-histone proteins can be dynamically regulated 
via a methylation-dependent fashion.   
Taken together, the above emerging evidence has generated tremendous interest in 
exploring beyond the canonical roles EZH2 and has revolutionized our understanding 





Figure 1.6 Existing mechanisms underlying EZH2 functions. 
Diagram extracted and modified from (Cavalli, 2012).    
A. Canonical EZH2-mediated gene silencing by recruitment of the core PRC2 
complex subunits comprising of EED, SUZ12 and EZH2 (top). Transcriptional 
repressor can occur when the transcription factor, e.g GATA4 is methylated and 
inhibited by EZH2 (bottom).   
B. EZH2-mediated gene activation. EZH2 can be recruited to interact and methylate 
AR leading to an enhancement of AR transcriptional activity (top). EZH2 can also 
form a ternary complex with RelA/RelB NF-κB subunits to activate NF-κB target 
genes transcription (middle). EZH2 can also bridge TCF/β-Catenin and ER/SRC-1 












1.2.6 Current therapeutics targeting EZH2 in cancer 
Aberrant alteration of epigenetic markers is a fundamental hallmark of human cancer 
progression. These alterations including both DNA hypermethylation and histone 
methylation and deacetylation and have been consistently observed in primary human 
tumor specimens in many studies (Baylin and Jones, 2011). Given EZH2 role in the 
regulation of cell-cycle, DNA damage repair, senescence and cell death and its 
involvement in many human cancers (Sauvageau and Sauvageau, 2010), it is certainly 
one of the prime target for the development of novel cancer therapeutic.  However, 
the frequent occurrence of genetic lesions affecting H3K27 also suggests that this 
epigenetic mark is under precise control by EZH2, which potentially present a 
challenge in the design of a safe and effective inhibitor targeting EZH2.  
 
                          
Figure 1.7 Chemical structure of 3-Deaza-neplanocin (DZNep) (Chiang, 1998) 
 
 To date, 3-Deazaneoplanocin A (DZNeP) is the only EZH2 inhibitor that 
could concurrently deplete EZH2 levels and inhibit H3K27me3. DZNep (Figure 1.7) 
is a cyclopentenyl analog of 3-deazaadenosine and it inhibits the activity of S-
adenosylhomocysteine (SAH) hydrolase, the enzyme responsible for the reversible 
hydrolysis of SAH to adenosine and homocysteine (Chiang, 1998). The inhibition 
33 
 
leads to an increase in intracellular SAH which in turn results in the inhibition of the 
S-adenosyl-Methionine (SAM) dependent Lysine methyltransferase activity of EZH2. 
Our lab was the first to show that DZNep can effectively inhibit EZH2 by promoting 
PRC2 complex degradation through proteosome-mediated pathway and indirectly 
inhibits EZH2 through effects on intracellular SAH concentrations (Tan et al., 2007). 
Importantly, DZNep can effectively lead to a global reduction of H3K27me3 and 
induces apoptosis in a variety of cancer cells (Tan et al., 2007). However, the increase 
in SAH levels induced by DZNep can also inhibit other histone methylation marks 
possibly by competing binding with Adenosylmethione (AdoMet) co-factor to the 
histone methyltransferases (HMTs) (Miranda et al., 2009). Interestingly, DZNep 
could reduce the levels of EZH2 protein but not the mRNA of EZH2 while siRNA 
knockdown of EZH2 decreased both protein and mRNA levels. Although, both 
treatments resulted in a reduction in H3K27 trimethylation, the pattern of genes that 
were de-repressed slightly differed (Tan et al., 2007). Interestingly, we have 
previously reported that the gene de-repression patterns significantly varied after 
combining DZNep with other epigenetic inhibitors such as DNA demethylating 
agents and HDAC inhibitors, suggesting that a subset of EZH2 repressed genes were 
repressed by additional epigenetic mechanisms (Sun et al., 2009).  In addition, the 
combination treatment using DZNep and HDAC inhibition has demonstrated 
synergistic effects on the proliferation and apoptosis in several breast cancer cell lines 
(Hayden et al., 2011).  
 In the past decade, there has been a growing interest in the development of 
inhibitors that specifically targets EZH2. Until recently, several small molecules 
EZH2 inhibitors specific for EZH2-mediated H3K27me3 were developed, and they 
are able to selectively kill several lymphomas harboring activating mutations of 
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EZH2. GlaxoSmithKline plc, Epizyme Inc., and Novartis AG have independently 
reported their small molecule EZH2 inhibitors, GSK126 (McCabe et al., 2012), 
EPZ005687 (Knutson et al., 2012) and EI1 (Qi et al., 2012) respectively within the 
same year in 2012. These small molecule inhibitors of EZH2 have showed promising 
efficacy in preclinical model of lymphomas with EZH2 activating mutations. All three 
small molecule inhibitors share the underlying mechanism to inhibit EZH2 histone 
methyltransferase activity by binding to the enzymatic SET domain of EZH2 and 
competitively inhibit SAM substrate from binding. Similarly, they are highly selective 
and specific to EZH2 with at least >50 fold selectivity against EZH1 for both 
EPZ005687 and EI1. However, the preliminary success of these inhibitors is largely 
limited to diffused large B-cell lymphomas (DLBCL) and follicular lymphomas with 
activating mutations of EZH2. Unlike the success in lymphomas, prostate and breast 
cancer cells were found to be highly resistant to GSK343 and GSK926 treatment 
despite almost complete inhibition on H3K27me3 (Verma, 2012b). According to that 
study, the growth inhibition IC50 is at least 20 folds higher the IC50 required for 
H3K27me3. The observation could either suggest that a near complete erasure of the 
H3K27me3 is required for growth inhibition or other H3K27me3 independent 
functions of EZH2 are required to be inactivated before growth inhibition could be 
observed. Given the recent progress with the introduction of the new class of EZH2 
inhibitors, it is now possible to dissect the H3K27me3 dependent functions from the 







1.3 Interferon Signaling Pathway  
1.3.1 The biology of interferon (IFN) signaling pathway 
The interferons (IFN) are a family of pleiotropic cytokines with diverse functions 
from mediating intracellular signaling during innate and adaptive immune response 
against viral and bacterial infections to tumor surveillance (Bach et al., 1997; 
Schroder et al., 2004). The IFNs are broadly categorized into type I and type II IFNs 
according to their homology in their coding sequence and substrate specificity. 
Similarly, both the type I and type II IFN receptor have multi-subunit structures which 
composed of at least two subunits: IFNAR1 and IFNAR2 subunit for the type I IFN 
receptor and IFNGR1 and IFNGR2 for the type II IFN receptor (Platanias, 2005).  
 The type I IFN comprises of several IFN-α subtypes, IFN-β, IFN-ω, and IFN-
τ, which are structurally similar and bind to the same Type I IFN receptor (IFNAR) 
comprising of the IFNAR1 and IFNAR2 subunits (Pestka et al., 2004; Trinchieri, 
2010). Although the type I IFNs are secreted ubiquitously at low levels by almost all 
cell types, the major production site for IFN-α and IFN-β are leukocytes and 
fibroblasts respectively (Bach et al., 1997; Platanias, 2005). IFN-α and IFN-β are 
usually secreted upon exposure to viruses, polypeptides, double-stranded DNA and 
cytokines (Bach et al., 1997).  
 On the contrary, IFN-γ is the only member of the type II IFN family which 
binds specifically to Type II IFN receptor. The type II IFN is typically secreted by T- 
lymphocytes, natural killer (NK) cells and antigen-presenting cells (APC) in response 
to various immunological stimuli. Of note, IFN-γ production is tightly regulated by 
cytokines released by APCs in both spatially and temporally precise fashion. Both 
interleukin (IL)- 12 and IL-18 have been associated to stimulate the production and 
secretion of IFN-γ during an innate immune response (Fukao et al., 2000; Munder et 
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al., 1998; Otani et al., 1999). In addition, IFN-γ is also pivotal in the expansion and 
activation of CD4
+
 T helper cells and CD8
+
 cytotoxic T cells responses (Ikeda et al., 
2002). Moreover, IFN-γ can also induce the expression of major histocompatibility 
complex (MHC) class I and II molecules and tumor associated antigens to enhance 
tumor surveillance (Fruh and Yang, 1999; Steimle et al., 1994). However, it is 
interesting to note that only IFN-γ can induce the expression of MHC class II but not 
by the type I IFNs (Marth et al., 1996). 
  
1.3.2 The signal transduction of IFN signaling 
The signal transduction of the IFN signaling involves the precise sequential receptor 
recruitment and activation of members from the Janus activated kinase (JAK 1-3 and 
Tyr2) and the Stats (STAT 1-6) family to regulate transcription expression of its 
target genes via binding to specific response elements on their promoters (Platanias, 
2005; Schroder et al., 2004). Upon binding to their respective activating ligands, the 
receptor subunits will undergo dimerization and ligand-dependent conformational 
change, followed by autophosphorylation and activation of the specific JAKs that they 
are associated with (Bach et al., 1997; Chen et al., 2004; Platanias, 2005). In this 
section, the underlying mechanisms and differences between the signal transduction 
of type I IFN and type II IFN signaling pathway will be summarized. 
 
1.3.2.1 Classical Type I IFN (IFN-α/β) signaling  
For the type I IFN signaling, the binding of IFN-α or other type I IFNs as mentioned 
in section 1.4.1 to the type I IFN receptor leads to the rapid autophosphorylation and 
activation of JAK1 and TYK2 which will regulate the phosphorylation and activation 
of downstream STAT proteins (Figure 1.8) (Darnell et al., 1994; Platanias, 2005; 
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Silvennoinen et al., 1993). It has been reported that STAT1, STAT2, STAT3 and 
STAT5 can be activated in response to type I IFNs stimulation (Darnell, 1997). 
Different type I IFNs binds to the same type I IFN receptor and shares a common 
pathway involving the same JAKs, TYK2 and JAK1 (Darnell et al., 1994). After the 
phosphorylation by JAKs, the activated STAT1 and STAT2 along with IRF9 forms 
the ISG factor 3 (ISGF3) transcriptional complexes. The ISGF3 transcriptional 
complex binds specifically to the IFN-stimulated response elements (ISREs) that are 
present in promoters of type I IFN regulated genes to initiate their gene transcription 
(Darnell, 1997; Platanias, 2005).  
 
1.3.2.2 Classical Type II IFN (IFN-γ) signaling  
As opposed to type I IFN signaling, the type II IFN ligand (IFN-γ) only binds 
specifically to the type II IFN receptor. To facilitate the rapid activation of IFN-γ 
signaling in response to viral infection, the IFNGR1 subunit is found to be interacting 
with JAK1 and IFNGR2 subunit is constitutively interacting with JAK2 even before 
any IFN-γ stimulation (Krause et al., 2002; Pestka et al., 2004). Upon the binding of 
IFN-γ ligand to the IFN-γ receptor, it will induce autophosphorylation and activation 
of Jak2, which thereby leads to the transphosphorylation of Jak1 by activated Jak2 
(Figure 1.8) (Bach et al., 1997; Platanias, 2005). The activated Jak1 phosphorylates 
the residue Y440 on each of the IFNGR1 chain forming two adjacent docking sites for 
the SH2 domains on Stat1 (Greenlund et al., 1994; Heim et al., 1995). Under 
unstimulated condition, Stat1 proteins are mostly localized in the cytosol in a latent 
monomeric form (Shuai et al., 1992). Upon IFN-γ stimuation, the IFNGR1-recruited 
Stat1 is phosphorylated by Jak2 near the end of its C-terminus at residue Tyr701. 
Such phosphorylation is essential for its activity and results in the formation of Stat1 
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homodimers which translocate into the nucleus to bind gamma-interferon activation 
site (GAS) promoter elements to initiate gene transcription (Darnell et al., 1994). The 
GAS promoter element is a 9 nucleotide long consensus sequence (TTNCNNNAA) 
and most IFN-γ activated genes would possess GAS elements in their promoters. In 
contrast to the type I IFNs, IFN-γ does not lead to the formation of ISGF3 complexes 
and cannot activate the transcription of genes that possess only ISREs in their 
promoters. Hence, the specificity of IFN-γ regulated genes is largely dependent on the 
presence of GAS elements in their gene promoters. Many of these IFN-γ regulated 
genes possess tumor suppressive functions which includes anti-apoptotic genes such 
as IRF1 (Tanaka et al., 1994), Fas/Fas ligand (Xu et al., 1998), caspase-1 (Chin et al., 
1997) and anti proliferative genes such as the Retinoblastoma protein (Rb) (Harvat 









                          
Figure 1.8 Type I and Type II interferon signaling pathway activation through 
JAK/STAT pathways.  
Schematic extracted and modified from (Platanias, 2005) All type I interferon (IFNs) 
bind a common receptor at the surface of human cells, which is known as the type I 
IFN receptor comprising of IFNAR1 and IFNAR2 subunits. The type I IFN receptor 
is associated with TYK2 and JAK1. Upon type I IFN receptor activation, the activated 
JAKs will phosphorylate STAT1 or STAT2 proteins allowing them to form the ISGF3 
complex along with IRF9. The ISGF3 complex will translocate into the nucleus and 
bind to target genes with the IFN stimulated response elements (ISREs) to initiate 
gene transcription. Additionally, the IFN-γ being the only type II IFN binds 
selectively only to the type II IFN receptor comprising of the IFNGR1 and IFNGR2 
subunits. IFN-γ binding to the type II IFN receptor causes autophosphorylation of 
JAK2 and leads to the transphosphorylation of JAK1. Activated JAK1 will in turn 
phosphorylate STAT1 at Y701, leading to the formation of a STAT1 homodimer 
complex and subsequent translocation into the nucleus. The STAT1 homodimer will 
bind to the GAS response elements that are present in the promoter of IFN-γ regulated 
genes, thereby initiating transcription of these genes. The consensus sequences of 
both ISRE and GAS element are as shown. N= any nucleotides.  
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1.3.3 Role of Type I IFN signaling in cancer 
In the previous section, the signal transduction of each type of IFN signaling pathway 
was introduced. In this section, the role of Type I IFN signaling, in particular, IFNα/β 
signaling will be summarized. It has been well established that the Type I IFNs 
function upstream of many pivotal signaling pathways. Apart from their namesake 
activity of interfering viral production, many studies have elucidated a myriad of 
other important cellular roles that the Type I IFNs are responsible for. For instance, 
they are key regulators of innate and adaptive immune responses and involve in the 
activation and differentiation of various immune cells. In recent years, as the roles of 
Type I IFNs in cancer have been further delineated and there was much excitement as 
its anti-angiogenic and pro-apoptotic effect, make it an obvious candidate for anti-
cancer therapy. Indeed, Type I IFNs has been used with limited success for the 
treatment of a few types of malignancies which includes melanoma, renal carcinoma, 
chronic myeloid leukemia and some B and T cell- lymphomas (Ferrantini et al., 2007; 
Moschos and Kirkwood, 2007). Despite Type I IFN treatment is still in use for some 
of these indications, it has been replaced by more efficacious targeted treatments. The 
severe adverse effects that accompany its therapeutic benefit have greatly limited its 
clinical use Side effects includes auto-immune and direct tissue toxicity which are 
likely to be the underlying causes for the hematological and neurological symptoms. 
It was previously reported that the type I IFN behaved like IFN-γ to inhibit the growth 
of carcinogen- induced primary and transplanted tumors (Dunn et al., 2005). 
Surprisely, unlike IFN-γ, the Type 1 IFN does not directly target the tumor cells. 
Instead, Type I IFN relies on the activation of hematopoietic cells such as Natural 
Killer (NK) cells to mediate its protective anti-tumor functions (Swann et al., 2007). 
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In addition, oncogenes such as Ras and HPV16E6E7 could target the Type I IFN 
signaling by down-regulating the IFN-inducing innate receptors, RIG-1 and TLR9 
which further suggest that Type I IFN modulates not only the infectiveness of the 
oncogenic viruses but also their ability to induce cellular transformation (Shmulevitz 
et al., 2010).  
1.3.4 Role of Type II (IFN-) signaling in cancer 
In the past decade, numerous reports have demonstrated IFN- to possess a wide 
variety of molecular and cellular functions of potential relevance to their application 
in cancer. IFN- is a cytokine that is well established to play a central role in 
coordinating tumor surveillance and its anti-tumor effects are due to a combination of 
direct anti-proliferative and indirect immune-mediated effects (Ikeda et al., 2002). 
Activation of the IFN- signaling leads to tumor suppressive effects through the 
induction of apoptosis-associated genes or inhibition of tumor suppressor genes to 
directly inhibit the proliferation of tumor cells. In vitro, activation of the IFN-γ 
signaling pathway could down-regulate the neu/HER2 oncogene and induce the 
cyclin-dependent kinase (CDK) inhibitor, p21, leading to the cell cycle arrest of 
prostate cancer cell lines and glioblastoma cells (Kominsky et al., 1998; Kominsky et 
al., 2000). Consistently in vitro, Li et al recently also showed that IFN-γ could induce 
autophagy accompanied by growth inhibition and cell death in human 
hepatocarcinoma (HCC) cells through the Interferon Regulatory Factor 1 (IRF1) (Li 
et al., 2012). Likewise in vivo, it has been previously shown that pretreatment with 
IFN-γ could protect the rats against the growth of hepatic tumors after partial 
hepatectomy (Karpoff et al., 1996). Crucially, a previous genome wide transcriptional 
profile of prostate cancer cells has revealed down-regulation of multiple IFN 
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responsive genes in approximately 30% of the 49 clinically characterized prostatic 
adenocarcinomas tumors (Shou et al., 2002). Their observations further demonstrated 
the direct link between the down regulation of the IFN-γ signaling and prostate cancer 
progression.  
 Apart from its direct tumor suppressive functions on cancer cells at the cellular 
level, IFN-γ signaling also plays an important role in orchestrating tumor surveillance 
and response towards cancer cells at the immune system level. IFN-γ was first 
identified as a glycoprotein that is produced and secreted by the T lymphocytes and 
NK cells in response to viral infection. One of its main immunological functions is to 
inhibit viral replication by inducing the expression of major histocompatibility 
complex (MHC) class I and II antigens (Sato et al., 1993). However, the induction of 
MHC molecules also enhances tumor cell immunogenicity by facilitating tumor 
recognition to promote macrophage mediated killing and stimulate T-lymphocytes to 
eliminate the cancer cells. Several studies have demonstrated that the IFN-γ signaling 
collaborate with lymphocytes to suppress the development of spontaneous epithelial 
carcinomas and carcinogen-induced sarcomas (Dunn et al., 2006; Kaplan et al., 1998; 
Shankaran et al., 2001). Likewise, injection of fibrosarcoma cells overexpressing the 
dominant-negative IFNGR1 ectopically leads to better tumor formation and offers 
resistance towards host rejection, demonstrating the crucial role of IFN-γ to detect and 
eliminate cancer cells (Dighe et al., 1994; Kaplan et al., 1998). This observation was 
supported by the statistics that approximately a third of the lung adenocarcinoma and 
melanoma cell lines have inactivating mutations in the IFN-γ signaling components. 
As such, this raised the possibility that some tumors that are resistant to IFN-γ 
treatment may be a mechanism utilized by cancer cells to evade tumor surveillance 
(Kaplan et al., 1998). In addition, mice that are deficient in IFNGR1 and STAT1 
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spontaneously developed tumors at a faster rate than the wild-type upon exposure to 
the carcinogen, which further highlighted the importance of IFN-γ signaling in host 
immune tumor surveillance (Shankaran et al., 2001).  
 
1.3.5 Clinical application of IFN-γ in human malignancies 
IFN-γ has long been regarded as a promising therapeutic agent against cancer as it is 
highly specific in distinguishing normal cells from the cancer cells. As summarized in 
Chapter 1.3.3, IFN-γ is produced by the activated T lymphocytes and possessed 
antiviral, anti-proliferative, apoptosis inducing and immunomodulatory functions. In 
the early 1970s, one of the major obstacles to study the clinical usage of IFN-γ in 
human was to purify sufficient quantity of IFN-γ that was pure enough to be 
administered in human subjects. Hence, the conduct of large randomized clinical trials 
to systematically study the role of IFN-γ in cancers in human subjects was almost 
impossible.  
 It was not until early 1980s, the success in cloning IFN-γ genes to generate 
large amount of recombinant IFN-γ led to the conduct of bigger clinical trials to 
systemically evaluate the safety and efficacy of IFN-γ in the treatment of human 
malignancies. Furthermore, the immunomodulatory properties of IFN- γ quickly 
inspired a wide variety of clinical applications which includes chronic granulomatous 
disease, fungal infections, autoimmune diseases such as rheumatoid arthritis, multiple 
sclerosis, inflammatory bowel disease and cancer (Miller et al., 2009). Due to its 
potent macrophage-activating and immune-stimulating properties, IFN-γ was first 
approved by the FDA for the treatment of chronic granulomatous disease in human 
(Group, 1991). Subsequently, advancing with the promising results in preliminary 
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clinical trials, several human malignancies such as metastatic renal cell carcinoma 
(RCC) (Otto et al., 1995), malignant melanoma, ovarian cancer and specific 
hematological cancers have been constitutively treated with exogenous IFN-γ with 
significant success (Miller et al., 2009). Despite its success in specific cancers, IFNs 
were found to be less effective in the treatment of other solid cancers (Hastie, 2008; 
Miller et al., 2009). For example in prostate cancer, many tumors and cell lines 
display lack of immunogenicity to IFN-γ stimulation and could be due to the down- 
regulation of MHC class I expression (Kuratsukuri et al., 2000; Wu et al., 2004) and 
the IFN-γ signaling (Shou et al., 2002) respectively . Consistently, Critchley et al 
have reported the impairment of IFN-γ signaling to be a common immune defect in 
patients of several human cancers, including breast cancer, melanoma, and 
gastrointestinal cancer (Critchley-Thorne et al., 2009). Likewise, the IFN-γ signaling 
pathway was also found to be down-regulated in T-lymphocytes that were isolated 
from metastatic melanoma patients (Critchley-Thorne et al., 2007). Hence, any 
impairment to the IFN-γ signaling pathway may compromise the tumor surveillance 
system and provide opportunities for abnormal or pre-cancerous cells to evade 
immune surveillance.  Furthermore, when IFN-γ is administrated at a high dose it can 
lead to adverse effects such as lethargy, depression and flu-like symptoms and further 









1.4 Aims of Study 
For decades, the Prostate Specific Antigen (PSA) test has been widely used to screen 
and assist detection of prostate cancer as discussed in Chapter 1.1. Although the PSA 
test has contributed to the decrease of prostate cancer related death, its high false 
positive rate has often led to misdiagnosis or overtreatment. Due to its inability to 
discriminate the indolent tumors from the aggressive prostate tumor, many patients 
with benign prostate tumors undergo therapeutic intervention which expose them to 
unnecessary risk. As such, there is a pressing need for the development of better 
prognostic biomarkers that are able to stratify the aggressive from the indolent 
prostate cancer patients to receive the appropriate treatment. 
 In the initial phase of this study, the Interferon Gamma Receptor 1 (IFNGR1) 
gene and multiple IFN-γ regulated genes were identified to be significantly down-
regulated specifically in advanced prostate cancer cell lines and tumors. The aim of 
this study is to dissect the role and mechanism underlying the down-regulation of 
IFN-γ signaling in advanced prostate cancer. The repressive signature that includes 
IFNGR1 and other IFN-γ regulated genes were subsequently evaluated for their 
association to different stages of prostate cancer tumors with the greater aim of 
developing IFNGR1 as a prognostic biomarker to distinguish the aggressive from the 
benign prostate tumors. In addition, we were interested to examine the therapeutic 
benefits of enhancing IFN-γ signaling through the restoration of IFNGR1 expression 
in advanced prostate cancer cells and murine xenograft model.     
 In the second phase of this study, my aim was to expand the study to other 
human cancers based on the molecular discoveries in prostate cancer. I was interested 
to examine if IFNGR1 is de-regulated in a similar fashion mediated by EZH2. Lastly, 
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I aim to evaluate the therapeutic potential of restoring the expression of IFNGR1 by 














































2.1 Cell culture and treatments 
All cell lines were obtained from ATCC (Manassas, VA). MB231, BT549, MCF7, 
T47D, BT474, MB361, MB415, MB436, Hs578T, MB157, PC3, DU145 cell lines 
were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS). VCap cells were grown in the addition of 1% sodium 
pyruvate and 1% sodium bicarbonate. SKBR3 cells were maintained in McCoy's 5A 
medium. HCC1806, HCC1937, 22RV1, and LnCap were maintained in RPMI 
medium supplemented with 10%FBS. HMEC and MCF10A normal breast epithelial 
cell line was grown in DMEM/F12 supplemented with 5% horse serum, 20ng/ml 
EGF, 0.5mg/ml hydrocortisone, 100ng/ml cholera toxin, 10μg/ml insulin, and 
penicillin/streptoMYCin (Invitrogen). RWPE1 and all its derivative sub-lines were 
grown in K-SFM with 50mg/ml BPE, 5ng/ml EGF (Invitrogen). All media were 
supplemented with 5000U/mL penicillin/streptomycin (Invitrogen). All cells were 
maintained at 37 °C with 5% CO2.  
 
2.2 Cryopreservation of cell lines 
All cell lines were grown and maintained for less than thirty passages. After which, 
frozen cells from earlier passages were retrieved from liquid nitrogen tank (-196°C) 
and thawed at 37°C in 5ml of their respective complete media. Cells were spun down 
at 1000rpm for 3 minutes and cell pellets were resuspended with fresh complete 
media and seeded into T25 flasks. Cells were allowed to stabilize for at least a week 
before experiments were conducted. For cryogenic preservation, cells were 
trypsinized and spun down at 1000rpm for 3 minutes. Cell pellets were then 
resuspended with freezing media (For HMECs and RWPE sublines: 90% culture 





 cells into each cryovials. Cells were first placed in Mr. Frosty cylinder 
(NALGENE) filled with 99% iso-propanol and kept at 80°C freezer. Cells were then 
transferred to liquid nitrogen tank after 24hrs. 
 
2.3 Transfection of Small interfering RNA 
siRNA transfections were conducted using Lipofectamine RNAiMax (Invitrogen) 
according to the manufacturer’s protocol. Target-specific siRNA and non-targeting 
control siRNA were purchased from 1st Base Singapore and Integrated DNA 
technologies (IDT) with the following target sequences respectively: EZH2 siRNA: 
5’-GACUCUGAAUGCAGUUGCU-3'; MYC siRNA: 5’-
UCCUGAGACAGAUCAGCAACAACCG-3’. All siRNA were designed by 1st Base 
Singapore and IDT respectively. For siRNA transfection, 2μl of siRNA (20μM) and 
2μl of RNAiMax were separately diluted into 100μl of OPTI-MEM (Invitrogen). 
After 5 minutes of incubation, the two diluents were mixed together and incubate for 
another 20 minutes before adding the transfection mixture into 800μl of complete 
medium-containing 6 well- plate, which was seeded with monolayer cells (1.5-3x 
10
5
cells/well) 18 hours prior transfection. The working concentration of siRNA was 
40nM. The transfected cells were either being trypsinized 24 hours post transfection 
and reseeded for downstream assays or changed media 24 hours post transfection and 
further incubated until time to harvest. 
 
2.4 Generation of stable over-expression cell lines 
To generate stable over-expression cell lines, target genes from their respective 
transient expression plasmids were subcloned into the PMN retroviral expression 
vector. pBabe puro HA PIK3CA E545K was purchased from Addgene and the coding 
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region was subcloned into pMN GFP/IRES retroviral vector (a gift from Dr Linda 
Penn's lab). PMN-MYC plasmid was from the courtesy of Dr. Linda Penn. To 
generate the RWPE sub-lines overexpressing either Myc or PI3K (E545K) active 
mutant, 4μg of plasmids and 10μl of Lipofectamine 2000 were separately diluted into 
100μl of OPTI-MEM (Invitrogen). After 5 minutes of incubation, the two diluents 
were mixed well and incubate for another 20 minutes before the addition of the 
transfection mixture into 800μl of OPTI-MEM containing 6 well plate (collagenI 
coated, BIOCOAT from BD pharmingen), which was seeded with monolayer 
Platinum-A retroviral packaging cells (CELL BIOLAB, INC.) 18 hours prior to 
transfection. After 6 hours of incubation, the transfection media were replaced by 
2.5mL of fresh antibiotic free complete DMEM. 48 hours post-transfection, the 
conditioned media from the transfected PlatinumA cells containing retroviruses 
packaged with target genes were collected and filtered through 0.45μm filter unit. 
Destination cells were seeded in 6 well plate 24 hours before the viral infection. 2mL 
of virus containing conditioned media were added to 1mL of complete media 
containing 3μl of 8μg/mL polybrene in the destination cells, followed by 90 minutes 
of centrifugation at 1800rpm. 48 hours after the viral infection, destination cells were 
trypsinized and expanded in culturing flasks. 1-2 weeks later, viral infected cells were 
sorted by Flow Cytometry based on their GFP expression. 
 
2.5 RNA extraction 
Cell pellets were first collected by harvesting monolayer cells with trypsin. 700μl of 
Qiazol (Invitrogen) was added to lyse the cell pellet, followed by the addition of 
200μl chloroform and centrifugation at 13.2kRPM for 15 minutes at 4ºC to separate 
RNA, DNA, and proteins from other cellular contents. After centrifugation, the top 
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liquid phase containing RNA was transferred to a fresh eppendorf tube followed by 
addition of 540μl of 100% ethanol. To purify RNA, miRNeasy mini kit (Qiagen) was 
used. Briefly, the samples were transferred to the column to allow RNA binding and 
flow through were accelerated by centrifugation at 10krpm for 30 seconds. Columns 
were washed once with 700ul RW1 buffer and twice with 500ul RPE buffer. Finally, 
RNA was eluted with 40ul RNAse-free water. RNA concentration and purity were 
assessed using NAnodrop ND-1000. 
 
2.6 cDNA conversion and Quantitative real-time PCR (RT-PCR) 
RNA samples were reverse transcribed and converted to single-stranded 
complementary DNA (cDNA) using High Capacity cDNA Reverse Transcription Kits 
(Applied Biosystems). Briefly, 750ng of RNA was diluted in 25ul nuclease-free water 
and added to 25μl of master mix containing 5μl RT buffer, 5μl random primers, 2μl 
dNTP mix, and 2.5μl MultiScribeTM reverse transcriptase and 10.5μl nuclease-free 
water. The reaction mix was then subjected to PCR in thermo cycler running for 10 
minutes at 25ºC followed by 2 hours at 37ºC. To perform quantitative real-time PCR, 
0.44μl of cDNA samples (15ng/μl) were added together with 0.4μl gene-specific 
primer mix (10μM) to 5ul of 2X master mix from KAPA SYBR® FAST qPCR Kits 
(Kapa Biosystems) and top-up to 10μl with nuclease-free water. Lastly, the reaction 
mix was amplified and quantified with PRISM 7900 Sequence Detection System 
(Applied Biosystems). 18S level was used as an internal control. All reactions were 
analyzed in an Applied Biosystems PRISM 7500 Fast Real-Time PCR system in 96-





Gene Forward Primer 5'3' Reverse Primer 5'3' 
18S CGAACGTCTGCCCTATCAACTT ACCCGTGGTCACCATGGTA 
IRF1 CATGGCTGGGACATCAACAA TTGTATCGGCCTGTGTGAATG 
TAP1 GGGCCTTGTCCAGTTCCAA GGTGAATGTCAGCCCCTGTAG 
IRF9 CCCGACCTCACCGATGAC TCTCGCGAAGCTGGATGTC 
OAS1 AGCACTGGTACCAAAATTGTAAGAAG CCTCGCTCCCAAGCATAGAC 
MX1 GACAGGACCATCGGAATCTTG ACGTCCACAACCTTGTCTTCAGT 
XAF1 GATGTGTCAGCAGAGCATGCA TGGCACTCATTGGCCTTATG 
IFI16 ACTGAGTACAACAAAGCCATTTGA TTGTGACATTGTCCTGTCCCCAC 
IFNGR1 GTGTGAGCAGGGCTGAGAT TCCCAATATACGATAGGGTTCA 
IFNAR1 ATGGGTGTTGTCCGCAG CTCCTGTTCCACCTCAGGAT 
EZH2 AGTGTGACCCTGACCTCTGT AGATGGTGCCAGCAATAGAT 
Table 2.1. Primers used for the quantitative-PCR of target genes 
 
2.7 Microarray Gene Expression Profiling and Analyses 
Total RNA was isolated by using Trizol (Invitrogen) and purified with the RNeasy 
Mini Kit (Qiagen). The microarray hybridization was performed using the Illumina 
Gene Expression Sentrix BeadChip HumanRef-8_V3 according to manufacturer’s 
protocol. Briefly, 500ng of RNA was reversed transcribed into cDNA and further 
processed to double-stranded cDNA. After purifying cDNA, biotnylated cRNA was 
generated and further purified. The biotiylated cRNA was generated and purified. The 
biotinylated cRNA was hybridized onto BeadChip and stained with streptavidin-Cy3 
after washing. Stained BeadChip was scanned using Illumina BeadArray Reader and 
images were stored with barcodes indicated. The scanned images were processed 
using Illumina GenomeStudio
TM 
and the exported raw data were imported into 
GeneSpringGXTM (Agilent Technologies) for further analysis. Gene expression data 
were deposted at NCBI Gene Expression Omnibus (GEO) repository database under 
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the accession number GSE43686. Using GeneSpringGX, the data were analyzed by 
selecting Illumina single color as experimental type and signals were normalized to 
median expression. Fold changes were analyzed by pairwise comparisons to vector 
control. To generate heatmaps median-normalized data represented in fold changes 
were processed by Cluster and visualized by Treeview (Eisen, 1998). 
2.8 Gene Ontology analysis 
Genes that were differently expressed with at least two-fold differences from the 
vector control after oncogenic transformation induced by either Myc or PI3K 
(E545K) mutant in RWPE1 benign immortalized prostate epithelial cells were 
separated into upregulated and downregulated genesets. The downregulated geneset 
was imported into Ingenuity Pathway Analyses (IPA) software for gene ontology 
analysis. From the analysis, signaling pathways and biological functions enriched in 
the imported genesets were obtained. Genes that appeared in the analyzed geneset and 
enriched in the biological function was indicated in the signalling network exported 
from IPA. 
 
2.9 Protein extraction 
Cell pellets were collected by harvesting monolayer cells with trypsin. For total 
protein extraction, cell pellets were then resuspended with 30ul to 40ul 
RadioImmunoPrecipitation Assay lysis buffer (50mM Tris-HCl pH7.4, 1mM EDTA, 
150mM NaCl, 1% Igepal CA630, 0.5% sodium deoxycholate, 1mM Na2VO4, 20mM 
NaF, 1mM PMSF, and Complete protease inhibitor (Roche)). Samples were incubated 
on ice for 30 minutes, vortexed for 15 seconds every 5 minutes. Samples were 
sonicated twice for 5 seconds followed by centrifugation at 13.2kRPM for 15 minutes 
at 4ºC. Supernatant was transferred to fresh eppendorf tubes and protein concentration 
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was estimated with DC Protein Assay (Bio-Rad) using BSA with known 
concentrations as standard and measured using Tecan XfluorTM software.  
 
2.10 Western Blotting 
Protein samples (15-25ug) were separated by 10% or 12% SDS-PAGE gel and 
subsequently transferred onto PVDF membrane (Millipore) using Trans-Blot SD 
Semi-Dry transfer cell (Bio-Rad). Membranes with immobilized proteins were 
blocked with 5% non-fat milk (Bio-Rad) or 5% BSA (Sigma) for 1 hour followed by 
primary antibodies for 1 hour and HRP-conjugated secondary antibodies for 1 hour. 
Membranes were incubated with chemoluminescent ECL Substrate Kit (GE 
Healthcare) and signals were detected using Kodak films. The blots were probed with 
primary antibodies against EED (07-368), SUZ12 (07-379), trimethylated H3-K27 
(07-449), Acetyl-Histone H3 (06-599), which were purchased from Millipore. 
IFNGR1 (GIR-94) and anti-IFI16 (1G7) were purchased from Santa Cruz. EZH2 
(AC22), P110α PI3K, p-AKT (T308), p-AKT (S473), pSTAT1Y701, total STAT1, 
Histone H3 (3H1) and cleaved PARP were purchased from Cell Signaling. Myc and 
Actin were purchased from Roche Applied Science and Sigma-Aldrich, respectively. 
Anti-Myc and anti-actin were purchased from Roche Applied Science and Sigma-
Aldrich, respectively. 
 
2.11 Immunohistochemistry (IHC) 
Tissue microarray slides (PR956, BR1503b, LC2083, and LV6161) were purchased 
from US Biomax. Staining and image analysis of tissue microarray were performed 
by Histopathology Department from Institute of Molecular and Cell Biology, Agency 
for Science, Technology, and Research (A*STAR), Singapore. Anti-EZH2 (D2C9 
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XP) antibody was purchased from Cell Signaling and anti-IFNGR1 antibody (GIR-
94), anti-c-Myc (9E10) antibody was purchased from Santa Cruz Biotechnology. 
Briefly, five-micron paraffin-embedded tissue sections cut, deparaffinized, 
rehydrated, antigens were retrieved by Proteinase K solution; sections were then 
incubated in 3% H2O2 at room temperature to block endogenous peroxidase. Slides 
were incubated in primary antibody against EZH2, c-Myc or IFNGR1 for 45 mins 
followed by 30 min incubation with anti-mouse Labelled Polymer (Dako, CA). 
Specificity of the immunostaining was determined by the inclusion of isotype-specific 
IgG as negative control. The detection system was DAB+ Substrate-Chromogen 
Solution (Dako).The sections were counterstained with hematoxylin.  
Slides were scanned at 20x using an Leica SCN400 slide scanner (Leica 
Microsystems, Germany). Images were exported to Slidepath Digital Image Hub 
(Leica Microsystems, Germany) for viewing. Tissue micro-array cores were analysed 
using the Measure Stained Cells algorithm of Slidepath Tissue IA software (Leica 
Microsystems, Germany). Data was collated using Microsoft Excel. Scanning and 
image analysis was performed by the Advanced Molecular Pathology Laboratory, 
IMCB, Singapore. 
 
2.12 Chromatin Immunoprecipitation (ChIP) 
Cells were expanded in 15cm petridish. To harvest for ChIP assay, cells were fixed 
with 3.7% paraformaldehyde for 20 minutes with gentle shaking followed by 
neutralization with 2mL 2M glycine for 5 minutes with gentle shaking. Fixed cells 
were washed twice with 10mL cold PBS and harvested by scrapping. Cell pellets 
were then lysed with 500μl SDS lysis buffer (1%SDS, 5mM EDTA, 50mM TrisHCl 
pH8) and sonicated for 6.5 minutes (30 seconds pulse on and 30 seconds pulse off) 
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followed by centrifugation at 13.2kRPM for 10 minutes. Supernatants were then 
transferred to 15mL Falcon tubes and top-up with Dilution buffer (1% TritonX100, 
2mM EDTA, 20mM TrisHCl pH8, 150mM NaCl) to 3mL. Samples were then pre-
cleared with 210μl of BSA blocked Protein A beads (Zymed) and 1μg of normal IgG 
for 4 hours with rotation at 4ºC. Pre-cleared chromatin was immunoprecipitated with 
10μg of specific antibodies against EZH2 (Active Motif), H3K27me3 (Upstate 07449) 
or rabbit IgG (Santa Cruz Biotechnology) as a control and rotated overnight at 4ºC. 
80μl of Protein A beads were added 16 hours later and further incubated for 1 hour. 
Beads were then washed 10 minutes each, once with 5mL TSEI buffer (0.1% NP40, 
1% TritonX100, 2mM EDTA, 20mM TrisHCl pH8, 150mM NaCl), once with 5mL 
TSEII (0.1% SDS, 1% TritonX100, 2mM EDTA, 20mM TrisHCl pH8, 500mM 
NaCl), once with 5mL Buffer III (0.25M LiCl, 1% NP40, 1% sodium deoxycholate, 
1mM EDTA, 10mM TrisHCl pH8), and once with 5mL TE Buffer (2mM EDTA, 
10mM TrisHCl pH8). Immunoprecipitated chromatins were eluted with 240μl SDS 
Elution Buffer (1%SDS, 10mM EDTA, 50mM TrisHCl pH8) and shaked at 65ºC for 
30 minutes. Supernatants were transferred to fresh eppendorf tubes and de-crosslinked 
for 16 hours at 65ºC. Purification of immunoprecipitated DNA was performed using 
PCR purification kit (Qiagen) following manufacturer’s protocol. The 
immunoprecipitated DNA was quantitated by real-time quantitative PCR using KAPA 
SyBr Fast qPCR kit (KAPA Biosystems) with the specific ChIP primers as listed in 
Table 2.2. Quantification of binding to the promoter was defined as the percentage of 
the whole cell lysate input DNA. The fold enrichment was derived by normalizing the 
specific antibody enriched against the IgG-enriched chromatin. CNR1 serves a 
positive control and Actin as a negative control. Significance of target genes was 
assessed relative to Actin level. 
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2.13 Dual Luciferase Reporter Assay 
STAT1-specific reporter plasmid pSTAT1, its negative control pGL4 empty vector, 
and pRL-null were purchased from Signosis. During transfection, 500ng 
pGL4/pSTAT1 and 20ng pRL-null were diluted in 50μl OPTI-MEM. After 5 minutes 
of incubation, 2.6μl of FugeneHD was added and further incubated for 20 minutes. 
The transfection mixtures were then added into 400μl of complete medium-containing 
24-well plate, which was seeded with monolayer RWPE cells 18 hours prior 
transfection. The media of the transfected cells was changed with fresh complete 
media 24 hours post transfection. Cells were harvested 48 hours post transfection and 
luciferase activity was detected using the Dual Luciferase system (Promega) 
following manufacturer’s protocol. To analyze luciferase activity, Firefly signals of 
pGL4/pSTAT1 were normalized to Renilla signals of pRL-null in respective samples. 
pSTAT1/pRL-null ratio were further normalized to pGL4/pRL-null ratio to obtain 
normalized values corrected for the changes of basic transcription activity for 
indicated treatment of the cells. 
 
2.14 Flow Assisted Cytometry Analysis (FACS) 
For the assessment of cell death, cells were harvested in 70% ethanol. Fixed cells 
were stained with Propidium Iodide (P.I) (50μg/mL). The stained cells were analyzed 
for DNA content by FACS in a FACSCalibur (Becton Dickinson Instrument). % of 
cell death was defined as the sub-G1 population quantified using the CellQuest 
software (Becton Dickinson). The percentage of dead cells or sub-G1 cells was 
calculated by comparing the results of each experiment to the results from DMSO-
treated cells. Each assay was repeated a minimum of three times, with results reported 




2.15 Methylation Specific PCR 
Bisulfite modification of DNA was carried out by using the EZ DNA methylation- 
Gold kit (ZYMO Research) according the manufacturer’s protocol. The CpG island 
DNA methylation status was determined by methylation specific PCR (MSP) as 
described previously (Jiang et al., 2008). MSP primers targeting the IFNGR1 
promoter for methylated sets includes: Forward primer M, 5'-
GTGTTTATTGTTGGGTGTTGC-3' and Reverse Primer M, 5'-
GTCACCGAAATCTATACCGAC-3'. For unmethylated sets includes: Forward 
Primer U, 5'-TGTTTATTGTTGGGTGTTGTGT-3' and Reverse Primer U, 5'-
TTCCATCACCAAAATCTATACCAA-3'. 
 
2.16 Anchorage-independent colony formation assay 
To assess anchorage-independent growth of RWPE1 transformed cells, 1x10
4
 cells 
were suspended in K-SFM containing 0.3 % agar, 10 % fetal bovine serum, and 
layered on K-SFM containing 0.6% agar and 10% FBS in 6-well plate. After 3 weeks, 
colonies were stained 18-24 hours with iodonitrotetrozolium chloride (Sigma). 
Colonies from three replicate wells were quantified using GelCount colony counter 
(Oxford Optronix). 
 
2.17 Prostatosphere Assay 
In order to obtain prostatospheres from either DU145 or LnCAP, exponentially 
growing cultures were dissociated to single cells by standard trypsinization, washed 
three times with PBS and plated at a density of 1x10
4
 cells/well in 6-well ultra-low 
attachment plates (Corning) containing 3ml of SCM medium (DMEM:F12 plus 10 
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ng/mL bFGF, 20 ng/mL EGF, 5 mg/mL insulin, and 0.4% BSA) supplemented with 
1% KO serum replacement (Invitrogen/Gibco). The cells were treated with DZNep or 
IFN-γ as indicated the next day and cultured for 7 days. 7 days old prostatospheres 
formed were stained with 4 μg/ml p-Iodonitrotetrazolium Violet (INT) overnight and 
were counted and analyzed using a GelCount™ automatic plate scanner (Oxford 
Optronics) and GelCount Version 0.025.1 software (Oxford Optronics). Plates were 
scanned at 1200 dpi and the colony detection algorithm was optimized for each cell 
type and culture time.  
 
2.18 CellTiter-Glo® Luminescent Cell Viability Assay 
The optimal cell seeding was determined empirically for all cell lines by examining 
the growth of a wide range of seeding densities in a 96-well format to identify 
conditions that permitted proliferation for 6 days. Cells were then plated at the 
optimal seeding density 24 h before siRNA or drug treatment in triplicate. Plates were 
incubated for 6 days at 37oC in 5% CO2. Cells were then lysed with CellTiter-Glo 
(CTG) (Promega) and chemiluminescent signal was detected with a microplate reader 
(TECAN). In addition, an untreated plate of cells was harvested at the time of drug or 
siRNA addition (T0) to quantify the starting number of cells. CTG values obtained 
after the 6 day treatment were expressed as percentages of the T0 value and plotted 
against time of treatment. Cells received 1-5μM of DZNep, 25ng/mL of IFN-γ and 
0.1-2.5μM of GSK343 unless stated otherwise for 72-96 h. 
 
2.19 DU145 Prostate Cancer Subcutaneous xenograft model 
For in vivo evaluation of DZNep and IFN-γ treatment, the experiments were 
conducted in compliance with animal protocol approved by the ASTAR-Biopolis 
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Institutional Animal Care and Use Committee (IACUC) of Singapore. DU145 cells 
were subcutaneously injected into 6-8 week male nude mice at 5x10
6
 cells, followed 
by treatment with vehicle, IFN-γ (1x107IU/kg) alone, DZNep (1mg/kg)  alone or 
combined DZNep (1mg/kg) with IFN-γ (1x107IU/kg). IFN-γ was administered by 
intraperitoneal injection daily and DZNep by subcutaneous injection on every 
alternating day over a duration of 38 days after average tumor size reached around 
150mm3. Tumors were measured by vernier calliper at least twice per week and 
tumors volume was calculated with formula: V=W*W*L/2. Each xenograft treatment 
arm comprised of 5–8 mice. Differences among groups and treatments were 
determined by ANOVA followed by t tests. (***p<0.001, n.s=not significant) Error 
bars represent means ± s.e.m. 
 
2.20 Statistical Analysis 
All in vitro experiments were repeated at least three times unless stated otherwise, and 
data are reported as means + s.e.m. Differences among groups and treatments were 
determined by ANOVA followed by t tests. p ≤ 0.05 was considered significant 
unless stated otherwise. All statistical tests and graphs are generated with Graphpad 
















CHAPTER 3: EZH2 MEDIATED REPRESSION OF 

















3.1 MYC or PI3K-mediated oncogenic transformation in prostate 
epithelial cells induces transcriptional inactivation of IFN-γ-STAT1 
signaling 
 
Gene amplification of MYC or constitutive activation of PI3K signaling pathway 
occurs frequently in advanced prostate cancer (Gurel et al., 2008; Jenkins et al., 1997; 
Majumder and Sellers, 2005; Sato et al., 1999). To investigate the molecular events 
induced by MYC or PI3K, an oncogene-induced transformation model was 
established with the immortalized prostate epithelial RWPE cells. The RWPE cells 
were first retroviral infected with MYC or a constitutively activating mutant of 
PIK3CA (E545K) and the resulting derivative cell lines were designated as RWPE1-
MYC, or RWPE1-PI3K clones respectively. Western blot analysis of the transformed 
cell lines confirmed the over-expression of c-Myc and the constitutive activation of 
the PI3K signaling pathway as reflected by the increase in S473 phosphorylation of 
AKT (Figure 3.1A).  
 To validate that these cell lines have undergone cellular transformation, soft 
agar assay was conducted to assess their ability to grow in the absence of anchorage. 
Indeed, both RWPE1-MYC and RWPE1-PI3K (E545K) cells could form more and 
bigger soft agar colonies as compared to the RWPE1-vector control cells (Figure 
3.1B-E). Significantly larger soft agar colonies fluorescing in green were observed in 
both RWPE1-MYC and RWPE1-PI3K (E545K), confirming that colonies are over-





             
                
          
Figure 3.1 Oncogenic Transformation of RWPE1 benign prostate epithelial cell 
line by MYC overexpression or PI3K (E545K) constitutive active mutant. 
 A. Western blot analysis of c-Myc expression and AKT phosphorylation 
  status at S473 in transformed RWPE1-MYC and RWPE1-PI3K cells. 
    B. Quantification of soft agar colonies which shows significant difference      
  (*p<0.05) in anchorage independent growth of RWPE1-MYC and  
  RWPE1- PI3K in comparison to RWPE1-Vector.  
 C-E.  Representative scanned image of the soft agar colonies of the  
  respective cell line as indicated (left), Phase-contrast microscopy  
  image of the soft agar colonies taken at 4x magnification (top right), 
  GFP fluorescent microscope image of the soft agar colonies taken at 4x 
  magnification (bottom right) showing the specificity of the gene  







 As oncogenic transformation is often coupled with epigenetic gene silencing, 
we performed gene expressing profiling using Illumina 24K human BeadArray-V3 
focusing on pathways and gene sets that are downregulated upon oncogenic 
transformation. Gene expression analysis led to the identification of 610 genes that 
were differentially expressed (with 2-fold cutoff, P<0.01). Subsequently, we 
identified a set of 344 genes that was downregulated in either MYC- or PI3K-
transformed RWPE1 cells as compared with the vector control RWPE1 cells (Figure 
3.2A).  
 To gain further insights into the biological function of these differentially 
regulated genes, we performed Ingenuity Pathway Analysis (IPA) on the 344 
downregulated genes identified. Interestingly, this gene set was found to be enriched 
for the canonical interferon signaling as the top gene network (P < 3 x10
-11
) (Figure 
3.2C). Furthermore, 64 out of 344 overlapping downregulated genes in the two 
transformed cell lines were identified to be interferon responsive genes (IFN genes) in 
the INTEREROME database (Figure 3.2B) which can be mapped at multiple levels in 
the IFN–STAT1 signaling cascade (Figure 3.3). The INTEREROME database 
consists of 1,823 Interferon Regulated Genes (IRGs) that were previously identified 
from multiple microarray and proteomic experiments where cells were treated with 
IFNs. Genes that were up or down regulated more than 1.5 fold relative to control 
samples were defined as IRGs.   
 Notably, IFNGR1 which encodes for the Interferon γ receptor 1 (also known 
as Type II IFN receptor) was downregulated, while IFNAR1, which encodes the 
subunit of the interferon α/β receptor, was not (Figure 3.3). From the introduction, we 
know that IFN-γ receptors and IFNα/β receptors are different in terms of structure, 
signal transduction and ligand specificity (Platanias, 2005). The IFN-γ receptors only 
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bind specifically to the IFN γ ligand which was markedly different from the ligand 
that binds and activates the IFN α/β receptors. Thus, these findings suggest that MYC 
or PI3K activation in benign prostate epithelial cells could induce a transcriptional 
























Top Canonical Pathways P-Value Ratio  
Interferon Signaling 3.13E
-11
 13/34 (0.382) 
Activation of IRF by Cytosolic PPR 5.35E
-06
 11/64 (0.172) 
PPR Recognition of Bacteria and Viruses 5.5E
-06
 12/77 (0.156) 
Hepatic Stellate Cell Activation 6.13E
-05
 15/140 (0.107) 
Aryl Hydrocarbon Receptor Signaling 4.94E
-04
 13/139 (0.094) 
       
Figure 3.2 Oncogenic transformation by MYC and PI3K induced transcriptional 
inactivation of IFN-γ-STAT1signaling pathway. 
 A. Unsupervised hierarchical clustering shows that 610 genes were  
  differentially regulated in either RWPE1-MYC and RWPE1-PI3K  
  cells compared to RWPE1-vector control cells (2-fold cutoff, P<0.01) 
  The colored scale bar represents the absolute fold change.  
 B. Venn diagram (not drawn to scale) shows the overlapping of genes 
  downregulated in RWPE1-MYC and RWPE1-PI3K cells with known 
  IFN genes in the INTERFEROM database. 
 C. Ingenuity Pathway Analysis (IPA) of genesets that were   
  downregulated in both RWPE1-MYC and RWPE1-PI3K. Interferon 
  signaling pathway emerged as the top gene network enriched in  






           
Figure 3.3 Graphical depiction of representative IFN genes in the IFN-STAT1 
pathway.  













 Loss of IFNGR1 is expected to impair cellular response to IFN- stimulation, 
resulting in the reduction of STAT1 transcriptional activity. The IFN-γ-induced 
STAT1 transcriptional activity was measured by a luciferase reporter assay. 
Subsequently, the results showed that the STAT1 activity was significantly reduced in 
both RWPE1-MYC and RWPE1-PI3K cells as compared to the vector control cells 
(Figure 3.4A).  
 This led us to our hypothesis that the downregulation of IFN-γ receptors on 
the cell surface of the transformed RWPE1-MYC and RWPE1-PI3K cells could 
explain for the decrease in sensitivity to IFN-γ treatment. Consistently, western 
blotting confirmed the downregulation of IFNGR1 protein expression and dampened 
the induction of STAT1 phosphorylation in response to IFN-γ treatment in RWPE1-
MYC and RWPE1-PI3K cells as compared with the vector control RWPE1 cells 
(Figure 3.4D). Quantitative RT-PCR (qRT-PCR) analysis further validated the gene 
expression array data by showing the specific down regulation of IFNGR1 (but not 
IFNAR1) and various IFN-γ regulated genes in both MYC- and PI3K-transformed 
RWPE1 cells (Figure 3.4B). Importantly, the downregulation of IFNGR1 and the 
IFN-γ regulated genes were also observed in prostate cancer cell lines (Figure 3.4C) 
and advanced human prostate tumors (Figure 3.10). Collectively, our results have 
suggested that benign prostate epithelial cells during oncogene-induced 
transformation and prostate cancer cells could potentially evade cell death by resisting 





       
 
    
Figure 3.4 Transformed cells were rendered less sensitive to IFN-γ stimulation 
due to a downregulation of IFNGR1 expression.      
 A. STAT1-driven luciferase reporter activity of indicated RWPE1 cell 
  lines treated with or without IFN-γ. 
 B-C. qRT-PCR analysis of IFNGR1 and multiple IFN genes in RWPE1- 
  MYC and RWPE1-PI3K cells as well as prostate cancer cell lines  
  normalized to RWPE1 control counterparts.   
 D. Western blot analysis showing the IFNGR1 and STAT1   










3.2 IFNGR1 is a direct target of EZH2 and is downregulated in 
advanced prostate cancer associated with MYC 
 
The mechanism underlying the loss of IFNGR1 and IFN-γ regulated genes could 
result from epigenetic modifications such as DNA methylation or histone 
modifications. Similarly, MYC and PI3K signaling have been previously implicated 
in regulating EZH2 expression or activity (Cha et al., 2005; Koh et al., 2011; Sander 
et al., 2008). Particularly, MYC was previously reported to induce EZH2 expression 
by negative regulation on miR-26a in prostate cancer cell lines and Burkitt’s 
Lymphoma cell lines (Borno et al., 2012; Koh et al., 2011; Sander et al., 2008). As 
EZH2 was shown to be overexpressed in advanced prostate cancer (Varambally et al., 
2002), it was postulated that EZH2 may be implicated in the repression of IFN-γ 
signaling either directly or indirectly.  
 Indeed, ectopic overexpression of EZH2 in RWPE1 cells was able to 
downregulate the expression of IFNGR1 and other IFN responsive genes (Figure 
3.5A), indicating that EZH2 likely plays a repressive role on the transcriptional 
regulation of these genes. Furthermore, in RWPE1-MYC cells, EZH2 knockdown 
restored the expression of IFNGR1 (Figure 3.5B, Left), which was not observed in 
RWPE1-PI3K cells (Figure 3.5B, Right). Moreover, in both scenarios, IFNAR1 was 
not affected by the manipulations on EZH2 level. Thus, we hypothesized that EZH2 
may directly repress IFNGR1 expression in the context of MYC-driven condition, 







                        
           
Figure 3.5 EZH2 specifically represses IFNGR1 but not IFNAR1 expression in 
the context of Myc overexpression.           
 A. qRT-PCR analysis of IFNGR1 and other IFN-γ regulated genes upon 
  ectopic expression of EZH2 in RWPE1 cells. 
 B. qRT-PCR analysis shows the restoration of IFNGR1 expression, but 
  not IFNAR1, following EZH2 knockdown in RWPE1-MYC cells but 










 MYC could upregulate EZH2 level either by repressing the expression of 
miR-26a (Borno et al., 2012; Koh et al., 2011; Sander et al., 2008), or by increasing 
its activity via counteracting AKT-mediated inhibitory phosphorylation of EZH2 on 
Serine 21 (Cha et al., 2005; Kaur and Cole, 2013). We found that MYC 
overexpression in RWPE cells led to a modest decrease in miR-26a, which was 
consistent with a modest induction of EZH2 mRNA expression (Figure 3.6A). 
Meanwhile, we detected concurrent marked reductions of AKT phosphorylation at 
Serine 473 and EZH2 phosphoryalation at Serine 21 in RWPE1-MYC cells (Figure 
3.6B).  
 On the contrary, constitutive PI3K activation in RWPE cells did not induce 
such changes in AKT and EZH2 (Figure 3.6B). This suggested that MYC over-
expression in our system was more likely to increase EZH2 activity through AKT 
inhibition, with the miR-26a-mediated mechanism less involved.  As such, we 
detected significant EZH2 enrichment in the vicinity of the promoter region of 
IFNGR1 in RWPE1-MYC cells through quantitative chromatin immunoprecipitation 
(ChIP) analyses (Figure 3.7A; as compared with the positive control CNR1). In 
contrast, EZH2 enrichment was barely detectable in RWPE1-PI3K or the control 
RWPE cells, indicating that EZH2 was not implicated in the repression of IFNGR1 in 
these cells (Figure 3.7A).  
 In addition, insignificant EZH2 enrichment was found in genes that were 
downstream of IFNGR1 in the IFN-γ signaling pathway (Figure 3.8). Therefore, the 
transcriptional inactivation of IFN-STAT1 signaling observed in MYC-driven cells 
stemmed from a direct suppression of IFNGR1 expression by EZH2. Consistent with 
the observations in transformed RWPE1-MYC cells, we found a significant EZH2 
enrichment in the IFNGR1 promoter in two prostate cancer cell lines, DU145 and PC3 
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which expresses high levels of MYC and were sensitive to MYC-depletion (Gurel et 
al., 2008; Tsuchiya et al., 2002) but not in LnCAP cells which is PTEN-deficient (Wu 
et al., 1998) but expresses a low level of MYC (Bernard et al., 2003) (Figure 3.7B). In 
comparison, we found IFNGR1 promoter DNA in RWPE1-PI3K cells and LnCap 
cells to be partially hypermethylated, which was however not seen in RWPE1, 
RWPE1-MYC and DU145 cells (Figure 3.9). Thus, using both transformed RWPE1 
cells and prostate cancer cell lines we concluded that EZH2-mediated repression of 
IFNGR1 was restricted to MYC-associated prostate cancer cells. On the other hand, 
the downregulation of IFNGR1 in PI3K-transformed RWPE1 or PTEN-deficient 
LnCap cells might be associated with the promoter DNA hypermethylation. In favour 
of an alternate mechanism underlying the repression of IFNGR1, an earlier study has 
reported that multiple IFN genes were epigenetically silenced by promoter hyper-
methylation after cellular immortalization (Kulaeva et al., 2003). The results from 
their study supported the hypothesis that DNA methylation could be an alternative 
mechanism that was responsible for the repression of IFNGR1 and other IFN genes 




                        
  
                                       
Figure 3.6 Myc mediated regulation on EZH2 expression.  
 A. Myc overexpression induced EZH2 expression via repression of miR-
  26a. (Left) Quantitative PCR showing the reduction of miR-26a  
  expression in  Myc overexpressing RWPE1 cells but not in miR-26b 
  expression. (Right) Quantitative PCR validating the over expression of 
  Myc in RWPE1 cells and lead to a corresponding increase in EZH2 
  transcriptional expression.  
 B. Western blotting validating the overexpression of c-myc, constitutive 
  active mutant of PI3K and phosphorylation status of AKT and EZH2 







                     
 
 
Figure 3.7 Enrichment of EZH2 binding at the promoter of IFNGR1 in MYC 
transformed RWPE1 cells and prostate cancer cells with high MYC expression.  
A. Schematic showing the ChIP primer locations with respect to the 
transcriptional start site (TSS) of the IFNGR1 promoter. 
 B. ChIP analysis showing the enrichment of EZH2 in the promoter of  
  IFNGR1 in RWPE1-MYC but not in RWPE1-PI3K and RWPE1- 
  vector control cells. 
 C. Enrichments of EZH2 in the IFNGR1 promoter in DU145 and PC3 but 
  not LnCap cells. EZH2 occupancy was determined as fold enrichment 
  over IgG control and further normalized to the ACTIN promoter. 






     
     
 
 
Figure 3.8 Insignificant enrichment of EZH2 binding to promoter of various 
downstream IFN- regulated genes. 
(A)  Schematic showing the ChIP primer locations with respect to the 
transcriptional start site (TSS) of the STAT1, MX1, OAS1 and IRF1 promoter. 
(B) ChIP followed by qPCR indicates insignificant enrichment of EZH2 on 
promoters of various IFN-γ regulated genes in RWPE1-MYC, RWPE1-PI3K 





                                      
Figure 3.9 DNA methylation as an alternative mechanism to repress IFNGR1 in 
RWPE1-PI3K cells and PTEN deficient LnCap cells expressing lower level of 
MYC. 
Methylation Specific PCR (MSP) analysis of IFNGR1 promoter in RWPE1 sublines 
and prostate cancer cell lines showed partial DNA methylation in LnCAP and 

















3.3 Inverse correlation between IFNGR1 and EZH2/MYC expression 
in clinical prostate cancer tumors  
 
To validate the down regulation of IFNGR1 and its association with EZH2 and MYC 
expression in prostate cancer tumors, we first chose to evaluate their transcriptional 
expression through meta-analysis on the Yu Prostrate (Yu et al., 2004) and Grasso 
Prostrate (Grasso et al., 2012) dataset downloaded from the Oncomine database. The 
Yu Prostate dataset consisted of 113 prostate tumors consisting of normal prostate 
epithelial tissue to metastatic prostate tumors. Consistent with EZH2’s role in prostate 
cancer progression, the dataset showed a significant upregulation (p<0.001) of EZH2 
as the disease transited from benign prostatic epithelium to metastatic prostate cancer 
(Figure 3.10). On the contrary, the clinical grading and staging were inversely 
correlated with the down regulation of IFNGR1 (p<0.01) and multiple IFN responsive 
genes during the disease progression (Figure 3.10).  
 To further validate our observations in Yu Prostate dataset, we performed 
meta-analysis on another independent study (Grasso et al., 2012). The Grasso Prostate 
dataset consisted of transcriptional profiles of 28 normal prostate tissue, 59 localized 
prostate tumors and 35 metastatic prostate tumors. In agreement with the Yu Prostate 
dataset, EZH2 (p<0.001) and MYC (p<0.001) expression were significantly higher in 
metastatic prostate tumors as compared to the normal prostate tissue and localized 
prostate tumors (Figure 3.11A, Top). Conversely, the expression of IFNGR1 and its 
downstream IFN-γ regulated genes were found to be significantly lower in metastatic 
prostate tumors as compared to the localized prostate tumors (p<0.001) and normal 
prostate tissue (p<0.001) (Figure 3.11A). Interestingly, when the localized and 
metastatic prostate tumors were further stratified according to their MYC expression 
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status, IFNGR1 expression was significantly lower (p<0.05) in the Hi-MYC group as 
compared to the Low-MYC group. On the contrary, the EZH2 expression was 
significantly higher in the Hi-MYC group (p<0.01). Hence, the inverse relationship 
between EZH2 and IFNGR1 expression in Hi-MYC prostate tumors, further 
suggested that EZH2 repressed IFNGR1 in the context of MYC driven prostate 
tumors.  
 To further verify the results of our meta-analyses, we performed IHC staining 
on a prostate cancer tissue microarray to evaluate the protein expression of IFNGR1, 
EZH2 and MYC on the same set tumor specimens. Similarly, the expression of 
IFNGR1 decreased as the disease progressed from normal prostate epithelium to 
metastatic prostate tumor. On the contrary, the expression of MYC and EZH2 were 
inversely associated to IFNGR1 expression and increased as the disease progressed to 
metastatic prostate cancer (Figure 3.12). Collectively, the results showed that the 
EZH2-mediated repression of IFNGR1 and the downstream IFN responsive genes in 






             
Figure 3.10 IFNGR1 and downstream IFN-γ regulated genes was downregulated 
and negatively correlates with EZH2 expression in advanced prostate cancer. 
Box plots showing the mRNA expression of MYC, EZH2, IFNGR1 and multiple IFN-
 regulated genes in prostate cancer tumors from the Yu Prostate data set (Yu et al., 
2004). Normal prostate epithelium tissue (n=23), Primary prostate cancer tumors 
(n=65), MT=metastatic prostate cancer tumors (n=25). *p<0.05, **p<0.01, 








Figure 3.11 Downregulation of IFNGR1 and IFN-γ responsive genes in 
metastatic prostate cancer and negatively correlated with EZH2 and MYC 
expression. 
Scatter plots generated from the gene expression profiles from the Grasso Prostate 





localized prostate cancer (PC, n=59) and metastatic prostate cancer (PC, n=35) 
(Grasso et al., 2012). The scatterplots illustrated:  
A. (Top) the inverse correlation between the gene expression of IFNGR1 with 
 EZH2 and MYC, (Bottom) the concurrent downregulation of IFN-γ regulated 
 genes  
B. (Left) a lower IFNGR1 expression in PC tumors with high MYC expression as 
 compared to tumors with lower MYC expression. (Right) EZH2 expression 
 positively correlated with MYC expression in the PC tumors. Hi-MYC 
 expressing tumors were defined as tumors with MYC expression level higher 
 than the median level and vice versa for Low-MYC group (*p<0.05, 







Figure 3.12 IFNGR1 expression decreased while EZH2 and MYC expression 
increased as the disease progressed from benign tissue to metastatic prostate 
cancer. 
Representative IHC images illustrating the IFNGR1, EZH2 and MYC expression in 
normal prostate tissue and prostate cancer tumors with different clinical stages as 
indicated. RxCx represented the coordinates of the tumor samples in the tissue 




3.4 EZH2 repression of IFNGR1 in prostate cancer is dependent on 
Myc overexpression  
 
Activation of IFN-γ-STAT1 signaling was known to be tumor suppressive through the 
induction a number of IFN responsive genes, including the apoptosis-promoting IRF1 
(Park et al., 2004). EZH2-mediated repression of IFNGR1 was expected to cause a 
reduced sensitivity to IFN-γ treatment, leading to defective activation of STAT1 
phosphorylation and downregulation of IFN- regulated genes. In agreement with our 
hypothesis, EZH2 knockdown in DU145 cells resulted in the induction of IFNGR1. 
The restoration of IFNGR1 expression increased the cellular response to IFN-γ 
stimulation, as reflected by the enhanced STAT1 activation through Tyr701 
phosphorylation and increased expression of IFI16, a downstream target of STAT1 
(Figure 3.13A).  
 Consistent with MYC being upstream of  EZH2 (Borno et al., 2012; Kaur and 
Cole, 2013; Koh et al., 2011; Sander et al., 2008), MYC knockdown in DU145 cells 
resulted in decreased EZH2 expression, giving rise to a similar elevation in IFNGR1 
protein level and STAT1 activation in response to increasing dosages of IFN-γ 
stimulation (Figure 3.13B). Expectedly, the increase in IFNGR1 level was 
independent of IFN-γ stimulation in both EZH2 and MYC knockdown experiments 
indicating that IFNGR1 was not a target of the IFN-γ signaling pathway. 
Subsequently, three well established IFN-γ regulated genes MX1, IRF1 and IFI16 
(Samarajiwa et al., 2009) were used as molecular reporters that were reflective of 
IFN-γ signaling activity. We further demonstrated that increased gene response to 
IFN-γ stimulation upon EZH2 knockdown was only limited to Hi-MYC DU145 and 
PC3 cells but not in Low-MYC LnCap cells (Figure 3.14). Furthermore, MYC 
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knockdown in DU145 cells markedly reduced the enrichments of both EZH2 and 
H3K27me3 marks in the IFNGR1 promoter (Figure 3.15), further supporting that 
EZH2-mediated repression of IFNGR1 was dependent on MYC overexpression.  
 
 
Figure 3.13 Genetic depletion of MYC and EZH2 restored the expression of 
IFNGR1 and sensitized DU145 cells to IFN-γ stimulation. 
 A. Western blot analysis of IFNGR1 expression and IFN- signaling upon 
  MYC knockdown in the presence of IFN- at indicted doses.  
 B. Western blot analysis of IFNGR1 expression and IFN signaling upon 












Figure 3.14 Genetic depletion of EZH2 increased transcriptional expression of 
downstream IFN-γ regulated genes in Hi-MYC prostate cancer cells  
Quantitative RT- PCR analysis of three well established IFN- regulated genes, MX1, 
IRF1 and IFI16 in DU145, PC3 and LnCAP cells. ***p<0.001, **p<0.01, *p<0.05. 
                                        
Figure 3.15 Genetic depletion of MYC reduced enrichment of EZH2 binding and 
H3K27me3 marks on the IFNGR1 promoter. 
ChIP analysis of EZH2 and H3K27me3 enrichments in the promoter of IFNGR1 in 




3.5 Inverse association between EZH2 and IFNGR1 in classical MYC 
driven Burkitt’s lymphoma  
 
To illustrate the relationship between MYC, EZH2 and IFNGR1 that we observed 
thus far was clinically relevant; we examined their relationship in several Burkitt’s 
Lymphoma datasets with Oncomine analysis. Burkitt's lymphoma (BL) is a highly 
aggressive B-cell non-Hodgkin lymphoma characterised by the translocation 
t(8;14)(q24;q32) in 70-80% of BL patients resulting in the amplification of the MYC 
oncogene (Molyneux et al., 2012). Overexpression of MYC often arises as a result of 
juxtaposition of MYC to the enhancer elements of one of the immunoglobulin genes: 
the heavy chain at 14q32; the kappa light chain at 2p12; or the lambda light chain at 
22q11 (Molyneux et al., 2012). Hence, Burkitt’s Lymphoma is an attractive disease 
model to prove our hypothesis that EZH2 mediated the repression of IFNGR1 and 
IFN-γ/STAT1 signaling pathway in the context of MYC overexpression. Using data 
from 2 Lymphoma dataset exported from Oncomine database, we performed meta-
analysis to study the association between transcriptional expression of MYC, EZH2 
and IFNGR1.  
 In agreement to our hypothesis, we observed that there was a significant 
upregulation of EZH2 (p<0.01) in the Hummel Lymphoma dataset (n=221) who have 
an overexpression of Myc (n=60, p<0.001) due to Ig-Myc gene fusion as compared 
patients who do not have the Ig-Myc gene fusion (Figure 3.16A). On the contrary, 
IFNGR1 expression (p<0.001) was downregulated along with other IFN-γ regulated 
genes such as IRF1 and IFI35, in same group of patients with the Ig-Myc fusion gene 
(Figure 3.16A). Consistently, transcriptional analysis of various Lymphoma subtypes 
also qualitatively demonstrated the inverse association between IFNGR1 and 
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EZH2/MYC transcriptional level. Therefore, the expression data from the Burkitt’s 
Lymphoma dataset indicated that the repression of IFNGR1 mediated by EZH2 in the 



















Figure 3.16 EZH2 mediated downregulation of IFNGR1 in Burkitt’s Lymphoma 
driven by Myc overexpression due to Ig-Myc fusion. 
 A. Box plots showing the mRNA expression of EZH2, MYC, IFNGR1 
  and several IFNγ responsive genes in Lymphoma samples with Ig- 
  MYC fusion from the Hummel dataset (Hummel et al., 2006).  
  **p<0.01, ***p<0.001, n.s= not significant, two-tailed student’s t-test. 
 B. Heatmap showing the mRNA expression of EZH2, MYC and IFNGR1 
  in various Lymphoma subtypes generated from the Basso   
  Lymphoma dataset (Basso et al., 2005). The cluster of samples  
  highlighted in the red box represents Burkitt’s Lymphoma samples 
  which are characterized by Myc overexpression due to the Ig-Myc  
  fusion. (1) Burkitt’s Lymphoma; n=127, (2) Centroblastic Lymphoma; 
  n=28, (3) Chronic Lymphoctic Leukemia; n=34, (4) Diffuse Large B-
  cell Lymphoma; n=41, (5) Embryonal Rhabdomyosarcoma; n=1, (6) 
  Folicular Lymphoma; n=6, (7) Hairy Cell Leukemia; n=16, (8)  
  Hodgkin’s Lymphoma; n=4, (9) Mantle Cell Lymphoma; n=8, (10) 
  Multiple Myeloma; n=1, (11) Plasma Cell Leukemia; n=3, Primary 





3.6 EZH2-mediated inactivation of IFN-γ-STAT1 signaling pathway 
confers survival advantages in MYC-associated prostate cancer cells 
 
To investigate if the EZH2-mediated repression of IFN--STAT1 signaling pathway 
would result in any functional consequences, we examined the effect of knocking 
down either MYC or EZH2 on proliferation and cell viability in DU145 cells.  Upon 
MYC or EZH2 knockdown, when combined with IFN-γ treatment, resulted in 
synergistic increase in cell death as confirmed by sub-G1 DNA (Figure 3.17A). 
Crucially, the enhanced apoptosis induced by the combination conditions were 
IFNGR1-dependent, as the addition of a specific IFNGR1 neutralizing antibody 
CD119, which presumably blocks the binding of IFN-γ ligand to the IFN-γ receptor, 
almost completely abolished this apoptosis induction (Figure 3.17A).  
 In contrast, MYC or EZH2 knockdown had no such an effect in LnCap cells 
(Figure 3.17B), further supporting that this killing effect was restricted to MYC-
associated cells and was not a result of off-target effect. Taken together, these 
findings support that MYC and EZH2 acted concertedly in the same pathway to 
promote proliferative and survival advantages through inactivation of IFN-γ-STAT1 
tumor suppressor pathway. Restoring the IFN-γ-STAT1 signaling following EZH2 
knockdown was able to sensitize the IFN-γ treatment in Myc-driven prostate cancer 






          
Figure 3.17 Synergistic increase in cell death induced by IFN-γ treatment after 
genetic depletion of either MYC or EZH2 could be rescued by IFNGR1 
neutralizing antibody. 
 A. Sub-G1 DNA assessment by FACS in DU145 cells treated with  
  siEZH2 or siMYC together with IFN-γ, in the presence or absence of 
  CD119, the IFNGR1 neutralizing antibody.  
 B. Sub-G1 DNA analysis by FACS in LnCap cells treated with siMYC or 















3.7 Pharmacologic depletion of EZH2 restores the IFNGR1 
expression and synergizes with IFN-γ for apoptosis induction  
 
To demonstrate a translational value of this finding, we next asked whether a 
therapeutic benefit of restoring IFN signaling could be achieved through a 
pharmacologic approach. Histone methylation inhibitor deazaneplanocin A (DZNep) 
was previously demonstrated to deplete components of the PRC2 complex and de-
repressed target genes of EZH2 (Tan et al., 2007).  
 Accordingly, we saw that pharmacological depletion of EZH2 by DZNep in 
DU145 cells was able to mimic the EZH2 knockdown. The depletion of EZH2 
induced the IFNGR1 expression, which, when combined with IFN-γ led to a strong 
induction of STAT1 phosphorylation, as well as IFI16 and other IFN-γ regulated 
genes’ expression (Figure 3.19 A&B). Consistently, the results were in agreement 
with the selective repression of IFNGR1 by EZH2 while the DZNep treatment did not 
change IFNAR1 expression (Figure 3.19 A&B).  
 Phenotypically, DZNep treatment mirrored the EZH2 knockdown to induce a 
robust apoptosis when combined with increasing doses of IFN-γ in DU145 but this 
was not observed in LnCap cells (Figure 3.20A). Similarly, such an induction of 
apoptosis was only seen in RWPE1-MYC cells, but not in RWPE1-PI3K or control 
RWPE1 cells (Figure 3.20B), further demonstrating the importance of MYC-
dependency. To further demonstrate that the apoptosis induced was specific to EZH2 
but not other epigenetic factors, DU145 prostate cancer cells treated with IFN-γ in 
combination with other epigenetic compounds such as histone deacetylase inhibitors 
SAHA and TSA as well as DNA methylation inhibitor 5’Aza did not give rise to such 
a response (Figure 3.18), underscoring an unique ability of DZNep in this scenario. 
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Unlike other IFN- regulated genes that were reported to be silence in human cancers 
by DNA methylation (Calmon et al., 2009; Kulaeva et al., 2003; Shou et al., 2002), 
we showed that IFNGR1 was a novel repressive target of EZH2. In addition, a time-
course cell viability assay also demonstrated that the combination treatment with 
DZNep and IFN-γ, induced strong cell death in DU145 cells but only induced a 
modest cell proliferation inhibition in the LnCAP cells (Figure 3.21).  
 
       
Figure 3.18 DU145 cells treated with various epigenetic inhibitors in combination 
with IFN-γ. 
FACS analysis showing the synergistic induction of cell death in DU145 cells when 
DZNep was added in combination with IFNγ but was not observed in other epigenetic 
inhibitors. DU145 cells were treated with various epigenetic inhibitors as stated and in 
the following doses: DZNep (2.5µM), 5-AZA (5µM), SAHA (0.75µM) and TSA 










                    
Figure 3.19 Pharmacological depletion of EZH2 could mimic siEZH2 to restore 
IFNGR1 expression and enhanced response to IFN-γ stimulation. 
 A. Quantitative PCR showing the increase in gene expression of IFNGR1 
  and various IFN responsive genes but not IFNAR1 after 72 hr of  
  DZNep (2.5μM) and IFNγ treatment.  
 B. Western blot analysis of IFNGR1 expression and IFN- signaling in 
  DU145 cells treated with DZNep (2.5μM), IFN-γ at indicated doses or 







    
                   
             
                        
Figure 3.20 Pharmacological depletion of EZH2 could induce synergistic increase 
in apoptosis when combined with IFN-γ treatment. 
 A. Sub-G1 DNA analysis demonstrating the synergistic effect between 
  DZNep and IFNγ to specifically induce cell death in DU145 and  
  LnCap cells treated with DZNep (2.5μM), IFN-γ at indicated doses or 
  both. ***p<0.001. 
 B. Sub-G1 DNA analysis demonstrating the synergistic effect between 
  DZNep and IFNγ to specifically induce cell death in RWPE1-MYC 
  cells but not RWPE1-PI3K cells. Cells were treated with either DMSO 






            
Figure 3.21 Pharmacological inhibition of EZH2 by DZNep, mimics genetic 
depletion of EZH2 by siRNA to synergistically sensitize DU145 cells to IFN-γ 
induced cell death and growth inhibition.  
Cell viability assay of DU145 and LnCap cells after co-treatment with DZNep 
(2.5M) and IFN- (25ng/mL) for indicated duration. 
 
 To further validate that the apoptosis induced by the drug combination was 
indeed due to the restoration of IFNGR1 after inhibiting EZH2, we showed that the 
apoptosis could be inhibited by the neutralizing antibody (CD119) of the IFN-γ 
receptor (Figure 3.22A). Moreover, increasing doses of CD119 further abolished the 
induction of STAT1 phosphorylation and PARP cleavage (Figure 3.22B), indicating 
that the inhibition of IFNGR1 and its downstream signaling could rescue the DU145 
cells from apoptosis.  
 At the cellular signaling level, we attempted to block the activation of IFN-γ 
signaling with Axon 1588, a small molecule inhibitor of STAT1 upstream activator, 
Jak2. Consistent with the observations by directly inhibiting IFNGR1 with CD119 
neutralizing antibody, DU145 cells was indeed rescued from IFN-γ induced apoptosis 
(Figure 3.22C) in a similar fashion. Taken together, these findings demonstrated that 
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the apoptosis induced by the combination of DZNep and IFN-γ was largely mediated 
through the specific activation of the IFN-γ signaling pathway.  
 Moreover, the combination of DZNep and IFN-γ was also able to efficiently 
inhibit the formation of DU145-derived prostatospheres that have the characteristics 
of prostate cancer initiating cells (Duhagon et al., 2010; Miki, 2007), while it had no 
effect on LnCap-derived prostatospheres (Figure 3.23A-C). Consistently, we detected 
a drastic increase in the expression of IFN- regulated genes in DU145 
prostatospheres upon the combination treatment (Figure 3.23D). The results indicated 
that DZNep was able to recapitulate the effects of EZH2 knockdown and synergized 












     
        
Figure 3.22 DZNep restores sensitivity to IFN-γ induced apoptosis and IFNGR1 
neutralizing antibody rescued DU145 from cell death. 
 A. Sub-G1 DNA analysis in DU145 cells treated with DZNep, IFN-γ  
  (red) or both (blue) in the presence or absence of IFNGR1 neutralizing 
  antibody CD119 in indicated doses. Cells are pre-treated with CD119 
  for 24h before the addition of DZNep or/and IFN-γ for another 72h. 
  Cell death was represented as the percentage of cell population with 
  reduced DNA in the sub-G1 region. Negative control cells were treated 
  with DMSO. 
 B. Western blot analysis of EZH2, IFN signaling and PARP cleavage in 
  DU145 cells treated as (A).  
 C. Sub-G1 DNA analysis in DU145 cells treated with DZNep/FN in the 
  presence or absence of JAK2 inhibitor Axon 1588. Cells are pre- 
  treated with Axon 1588 for 24h before the addition of DZNep or/and 
  IFN-γ for another 72h. Cell death was represented as the percentage of 
  cell population with reduced DNA in the sub-G1 region. Negative  
  control cells were treated with DMSO. 
 D. Western blot analysis of EZH2, IFN signaling and PARP cleavage in 





                 
          
 
Figure 3.23 Combinatorial treatment with DZNep and IFNγ could effectively 
inhibit the formation of DU145 prostatospheres.  
 A. Prostatosphere formation assay over duration of 7-10 days showing the 
  effectiveness of combining low doses of DZNep with IFNγ to inhibit 
  the formation of prostatospheres in DU145 cells but not in B. LnCap 
  cells.  
 C. Representative phase contrast microscopy images of the   
  prostatospheres taken at 10x magnification after treatment with DZNep 
  and IFNγ for 72h. Dosage of DZNep added were as indicated.  
 D. Quantitative PCR showing the enhanced response to IFN-γ stimulation 
  after DZNep treatment as reflected by the up-regulation of IFN-  
  regulated genes, IFI16, IRF1 and OAS1 in DU145 cells but not  
  LnCap cells. The difference in expression was relative to the negative 
  control cells treated with DMSO. 
A B 
C 




3.8 Pharmacological inhibition of H3K27me3 alone is insufficient to 
sensitize cancer cells to IFN-γ treatment 
 
Recently, small molecule EZH2 inhibitors that specifically target EZH2-mediated 
H3K27me3 were developed and were able to selectively kill lymphomas harboring 
EZH2 activating mutations (Knutson et al., 2012; McCabe et al., 2012; Qi et al., 2012; 
Verma, 2012a). We thus sought to determine whether these EZH2-H3K27me3 
specific inhibitors would have a similar effect to EZH2 knockdown.  
 To our surprise, DU145 cells treated with such an EZH2 inhibitor (GSK343) 
up to 2.5 µM for 72 hours did not show an induction of IFNGR1, despite the evidence 
that EZH2-assoicated H3K27me3 was completely inhibited by GSK343 even at a low 
concentration of 0.1 µM (Figure 3.24A). In contrast, DZNep, which depleted EZH2, 
along with two other PRC2 proteins EED and SUZ12, induced the expression of 
IFNGR1, albeit at a much lower efficiency to deplete H3K27me3 (Figure 3.24A). 
Accordingly, in contrast to DZNep/IFN-γ combination treatment, we failed to see an 
apoptotic effect of GSK343/IFN-γ combination treatment in DU145 cells (Figure 
3.24B).  In addition to IFNGR1, we also showed that DZNep treatment in DU145 
cells was able to induce the expression of another known EZH2 target ADRB2, while 
GSK343 was unable to achieve this (Figure 3.24C).  
 Thus, these findings suggested that although H3K27me3 was a repressive 
mark associated with PRC2 activity, simply inhibiting H3K27 tri-methylation with 
GSK343, without affecting the PRC2 complex, was insufficient to induce IFNGR1 
expression and hence unable to recapitulate the effect of depleting EZH2. Additional 
mechanisms might be required to coordinate with H3K27me3 to implement PRC2-






Figure 3.24 Inhibition of H3K27 tri-methylation alone was insufficient to restore 
IFNGR1 and it required the depletion of EZH2 and other components of the 
PRC2 complex to restore the expression of IFNGR1. 
A. Western blot analysis of IFNGR1, PRC2 proteins, H3K27me3 in  
 DU145 cells treated with DZNep or GSK343 as indicated for 72h.  
B. Sub-G1 DNA analysis in DU145 cells treated with DZNep/IFN-γ or 
 GSK343/IFN-γ as indicated for 72h. Cell death was represented as the 
 percentage of cell population with reduced DNA in the sub-G1 region. 
 Negative control cells are treated with DMSO.  
C. Quantitative RT- PCR analysis of IFNGR1 and ADRB2 expression in DU145 
cells after 72 hours of treatment with either DZNep or GSK343 at indicated 
doses.  ADRB2 was a known target gene of EZH2. The relative expression of 
IFNGR1 and ADRB2 were expressed as fold change after normalizing to its 





3.9 Therapeutic effect of combined DZNep and IFN-γ treatment in 
vivo 
 
To confirm the above findings in vivo, we established the DU145 xenografts in 
athymic mice and treated them with vehicle, DZNep, IFN-γ, or both. Treatment with 
DZNep or IFN-γ alone slowed down the tumor growth, while the combination 
treatment resulted in a complete tumor growth arrest in average (p<0.01) (Figure 
3.25A) and a few of these tumors even showed tumor repression (data not shown). 
Throughout the study, both single or combination treatment were well tolerated in 
mice without overt signs of toxicity and minimal weight loss (Figure 3.25B). In 
addition, post-mortem autopsy of the nude mice receiving the combination treatment 
also displayed minimal changes to the vital organs (data not shown) further suggested 
the potential of developing this combination therapy for clinical use.  
 Immunohistochemistry (IHC) analyses of tumors resected from the mice at 
end point, confirmed the downregulation of EZH2 and upregulation of IFNGR1 
within the tumors treated with DZNep or DZNep combined with IFN-γ (Figure 
3.26A). Furthermore, western blot analyses of the cell lysates from these tumors 
showed enhanced STAT1 Y701 phosphorylation and PARP cleavage in tumors under 
the combination treatment, indicative of increased apoptosis as a result of increased 
IFN-γ signaling activity (Figure 3.26B). Thus, the combination of DZNep and IFN-γ 
was consistently effective in the xenograft tumor model and was able to induce the 
expected molecular changes within the tumors. However, it was observed that not all 
tumors treated with DZNep and IFN- displayed an increase in STAT1 Y701 
phosphorylation and PARP cleavage. One potential drawback of any xenograft model 
was that, small samples extracted for downstream assays might not be representative 
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of an entire tumor. Although the extraction of multiple samples from different sites of 
the same tumor could potential circumvent this problem, a majority of the tumors 
treated with DZNep and IFN-γ were either tumorstatic or regressed to below 150mm3. 
In view that the tumor samples were limited due their small volume, sampling from 
multiple sites of the tumors was technically not feasible. However, it was noticeable 
that a majority of the tumors treated with DZNep and IFN-γ did demonstrate an 
increase in cleaved PARP and enhanced STAT1 activation as compared to the tumors 


















                    
 
                       
Figure 3.25 Therapeutic effect of DZNep/IFN-γ in vivo.  
 A. DU145 xenograft tumor growth in male athymic nude mice treated 
  with vehicle (n=5) or IFN (1x107IU/kg, n=6) or DZNep (1 mg/kg, 
  n=7) or both (n=8). Mean tumor volume  s.e.m. was shown  
  ***p<0.001. n.s= not significant. 
 B. Body weight change ( s.e.m) during the drug treatment. n.s= not  










Figure 3.26 DZNep could restore IFNGR1 expression in vivo and sensitized 
DU145 tumors to IFN-γ induced cell death. 
 A. Immunohistochemistry analysis of EZH2 and IFNGR1 expression in 
  tissue sections taken from DU145 xenografts after the treatment in  
  Figure 3.19A. 
 B. Western blot analysis of indicated proteins in resected DU145  


















CHAPTER 4: EZH2-MEDIATED IFNGR1 SILENCING 


















4.1 EZH2-mediated IFNGR1 silencing occurs widely in human 
cancers 
 
To expand our findings from advanced prostate cancer, we seek to evaluate if EZH2-
mediated IFNGR1 silencing could have occur and contributed to oncogenesis in other 
human cancers. To narrow down our search and to identify human cancers that were 
likely to experience EZH2 mediated IFNGR1 silencing, we have shortlisted human 
cancers datasets with IFNGR1 downregulated and a corresponding upregulation of 
EZH2. Based on preliminary Oncomine analysis, we observed that the upregulation of 
EZH2 was indeed accompanied by the down regulation of IFNGR1 in many human 
cancers (Figure 4.1). Specifically, it was more prevalent in subsets of these cancers, 
such as luminal breast cancer and small cell lung cancer (SCLC) (Figure 4.2 & 4.7), 
suggesting the potential usage of IFNGR1 as a biomarker to further stratify these 
unique group of patients that will most likely to respond to the combination treatment 
of DZNep and IFN-γ. Similarly, the inverse correlation between the EZH2 and 
IFNGR1 transcription levels was able to further stratify the Myc-driven Burkitt’s 
Lymphoma from other forms of Lymphomas (Figure 3.13).  
 Hence in this chapter, our main objective was to extrapolate our findings in the 
prostate cancer model and examine the efficacy of the DZNep and IFN-γ co-treatment 
in cancer cell lines with defective IFN-γ signaling due to repression of IFNGR1 







                                
Figure 4.1 Upregulation of EZH2 and downregulation of IFNGR1 in multiple 
human cancers.  
Oncomine analysis showing the upregulation of EZH2 was companied by the down 
regulation of IFNGR1 in many datasets of various cancer types. Only datasets with a 
differential expression of at least 1.5 folds and a p-value of <0.001 as compared to the 
normal sample, will be considered as positive hits. Red represents upregulation and 








4.2 Negative correlation between IFNGR1 and EZH2 in luminal 
breast cancer but not in basal breast cancer  
 
In our previous study, our lab has unraveled an unexpected role of EZH2 in 
conferring the constitutive activation of NF-kB target gene expression in ER-negative 
basal-like breast cancer cells instead of its canonical role as an epigenetic gene 
silencer. In that study, we showed that EZH2 in breast cancer cells undergoes a 
functional switch that was largely dependent on the ER status of the breast cancer 
tumor (Lee et al., 2011). In addition, this novel function of EZH2 as a transcriptional 
activator was independent of its histone methyltransferase activity and requires the 
physical interaction with RelA/RelB to induce the transcriptional expression of NF-
kB targets. On the contrary, EZH2 represses NF-kB target gene expression by 
interacting with ER and mediating repressive histone methylation on their promoters, 
particularly in ER+ luminal breast cancer cells. As EZH2 could manifest its 
oncogenic functions depending on its molecular context, we chose to further validate 
the context-dependency of EZH2-mediated IFNGR1 repression in breast cancer. In 
order to test our hypothesis that IFNGR1 expression could stratify the molecular 
subtype of breast cancer cells, we carried out a meta-gene expression analysis on the 
expression of IFNGR1 using the GOBO database. The Gene expression-based 
Outcome for Breast cancer Online (GOBO) allows us to rapidly the gene expression 
of IFNGR1 and EZH2 and to associate with survival outcome across the entire breast 
cancer data set consisting of 1881 breast cancer tumor samples and 51 breast cancer 
cell lines.  
 Intriguingly, we found that IFNGR1 was transcriptional expressed at a much 
lower level in luminal breast cancer cell lines as compared to the Basal A or Basal B 
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breast cancer cell lines (Figure 4.2A, Left). Similarly, IFNGR1 transcriptional 
expression was found to be lower in ER+ breast cancer cells which belonged to the 
luminal breast cancer subtype. On the contrary, IFNGR1 was expressed at a much 
higher level in triple negative breast cancer cells which were usually of basal origin 
(Figure 4.2A, Right). Again, IFNGR1 expression could consistently stratify the breast 
cancer tumors according to their origin, whether it was luminal or basal subtype. 
Interestingly, lower IFNGR1 expression in the luminal B breast cancer tumors (Figure 
4.2B, Left) negatively correlated with a higher expression of EZH2 (Figure 4.2B, 













                            
            
Figure 4.2 Inverse association between EZH2 and IFNGR1 expression observed 
in luminal breast cancer cell lines and tumors.   
 A. GOBO analysis generated box plots showing the mRNA expression 
  (Log2) of EZH2 (left) and IFNGR1 (right) in 1881 sample breast tumor 
  dataset which were further catergorized according to their molecular 
  subtype. Error bars, means.e.m. 
 B. Boxplots generated from GOBO analysis on a panel of breast cancer 
  cell lines illustrating that the expression of IFNGR1 was significantly 
  lower in luminal and ER+ breast cancer cell lines as compared to other 









 To validate the down regulation of IFNGR1 and its negative correlation with 
EZH2 in luminal breast cancer (BC), western analysis was performed on 14 BC cell 
lines. Of which, 6 luminal BC cell lines (SKBr3, MCF7, BT474, T47D, MB361 and 
MB415) and 8 basal BC cell lines (MB468, HCC1806, HCC1937, MB231, BT549, 
HS578T, MB436 and MB157) was selected to be analyzed for their EZH2 and 
IFNGR1 expression. Subsequently, the western blot results confirmed the 
downregulation of IFNGR1 protein in ER
+
 luminal BC but not in ER
-
 basal BC cell 
lines (Figure 4.3A). In addition, immunohistochemistry (IHC) analysis on two 
luminal ER
+
 primary tumor specimen in comparison to the basal ER
- 
counterpart 
which consistently demonstrated the negative correlation between the expression of 
EZH2 and IFNGR1 (Figure 4.3B).  
  Notably, IFNGR1 expression in vast majority of the luminal BC cells was 
strikingly lower than the basal BC cells (Figure 4.3A). Although, there was no distinct 
difference between the expression of EZH2 in luminal and BC cells, the negative 
correlation between EZH2 and IFNGR1 expression was obvious only in the luminal 
BC cells. Unexpectedly, the negative correlation between EZH2 and IFNGR1 were 
also observed in several basal breast cancer cell lines such as HCC1937, MB436 and 
MB231 which expressed high level of EZH2 and lower IFNGR1 as compared to the 
rest of the basal BC cell lines. However, we speculated that the lower IFNGR1 levels 
in these basal BC cells are independent of the increase in EZH2 levels and we sought 








   
 
 
Figure 4.3 Inverse association between IFNGR1 and EZH2 expression in ER+ 
luminal breast cancer but not in ER- basal breast cancer. 
 A. Western blot analysis of IFNGR1 and EZH2 expression in a panel of 
  luminal and basal-like breast cancer cell lines. 
 B. Representative IHC imaging at 20x magnification showing the  
  IFNGR1 and EZH2 expression in ER+ and ER- breast tumors. Scale 







4.2 EZH2 mediated repression of IFNGR1 in luminal breast cancer 
cells but not basal breast cancer cells 
 
To address the disparity that we have observed in (Figure 4.3A), we have selected two 
breast cancer cell lines, MCF7 (luminal) and MDA-MB-231 cells (MB231) (basal) 
cells as our cellular model for further analyses. In the Chapter 3, we have established 
the mechanism underlying the repression of IFNGR1 mediated by EZH2 in prostate 
cancer cells. In this Chapter, similar experiments were conducted on both MCF7 
(luminal breast cancer cell line) and MB231 (basal breast cancer cell line) to evaluate 
our hypothesis that the repression of IFNGR1 mediated by EZH2 occurs specifically 
in luminal but not basal breast cancer cells.   
 Expectedly, EZH2 knockdown or DZNep treatment in ER
+
 luminal MCF7 BC 
cells led to an induction of IFNGR1 at both mRNA and protein levels but this was not 
observed in ER
-
 basal-like MB231 breast cancer cells (Figure 4.4A&B). Thus, the 
results strongly suggested that the EZH2 mediated repression of IFNGR1 was limited 
to luminal breast cancer line, MCF7 but not in the basal breast cancer cell line, 
MB231. In addition, ChIP analysis showed the enrichments of EZH2 and H3K27me3 
in the IFNGR1 promoter in MCF7 but not MB-231 cells (Figure 4.4C). Taken 
together, the results strongly suggested that IFNGR1 was not a target of EZH2 in ER
-
 
basal breast cancer cells despite of high EZH2 expression in some basal BC cell lines. 
As such, our results have illustrated that the repression of IFNGR1 mediated by EZH2 
was largely limited to the ER
+






             
 
 
Figure 4.4 EZH2 mediates IFNGR1 gene silencing in luminal breast cancer cells 
(MCF7) but not in basal breast cancer cells (MB231). 
  A. qRT- PCR analysis of IFNGR1 mRNA in MCF7 (red) and MB231  
  (blue) cells treated with siEZH2. *p<0.05. The relative expression of 
  IFNGR1 was expressed as fold change after normalizing to its negative 
  control treated with non-specific oligos.  
B. Western blotting of IFNGR1 and EZH2 in MCF-7 cells and MB231 
cells treated with siEZH2 or DZNep (2.5μM) for 72hrs.  
 C. ChIP analysis of EZH2 and H3K27me3 enrichments in the IFNGR1 
  promoter in MCF7 (red) vs MB231 (blue) cells. The enrichment was 







4.3 EZH2/IFNGR1 status predicts responsiveness to DZNep and 
IFN-γ treatment in luminal breast cancer cells 
 
To validate that the restoration of IFNGR1 in the luminal breast cancer cells upon 
EZH2 inhibition was functional, we evaluated a panel of breast cancer cells consisting 
of luminal and basal origin for their response towards DZNep and IFN-γ treatment. 
As expected, the combination of DZNep and IFN-γ resulted in robust apoptosis in 
luminal MCF-7 and T47D cells, but not in basal-like cell lines (Figure 4.5A). In 
addition, the immortalized human mammary epithelial cells (HMEC) which were 
benign and non-transformed were also resistant to the DZNep and IFN-γ treating. 
Hence, the combination treatment was selectively potent towards BC cells with 
defective IFN-γ signaling due to the repression of IFNGR1 mediated by EZH2 which 
further exemplified its potential to be developed for clinical use. 
 Consistently, both MCF-7 and T47D luminal breast cancer cells were sensitive 
to the combination treatment and the DZNep treatment could restore IFNGR1 
expression with increased STAT1 activation and induced PARP cleavage when co-
treated with IFN-γ (Figure 4.5B). The results demonstrated that EZH2 could repress 
IFNGR1 expression in luminal breast cancer cells in a similar fashion as the advanced 
prostate cancer cells in Chapter 3. Thus, EZH2 represses IFNGR1 expression and 
render susceptibility of the ER+ luminal breast cancer cells to the combination 
treatment with DZNep and IFN-γ. Importantly, our result demonstrated the diagnostic 
potential of IFNGR1 as a biomarker to stratify the basal breast cancer from the 






                  
Figure 4.5 Combinatorial treatment of luminal breast cancer cell lines (T47D 
and MCF7) with DZNep and IFN-γ induced synergistic apoptosis. 
 A. Sub-G1 DNA analysis of a panel of luminal and basal breast cancer 
  cell lines treated with DZNep in combination with increasing doses of 
  IFN-γ as indicated for 72h. Cell death is represented as the percentage 
  of cell population with reduced DNA in the sub-G1 region. Negative 
  control cells are treated with DMSO.  
B. Western blotting of indicated proteins in T47D and MCF7 cells treated 






4.4 Inverse EZH2/IFNGR1 status predicts poor Distant Metastasis 
Free Survival in ER
+ 
breast cancer patients   
 
In order to evaluate the potential of utilizing the inverse relationship between the 
EZH2 and IFNGR1 expression as a predictive biomarker, meta-gene expression 
analysis on a breast cancer data set consisting of 1881 breast cancer tumors was 
performed (Neve et al., 2006). The analysis allowed us to examine the Distant 
Metastasis Free Survival (DMFS) of these breast cancer patients that were stratified 
according the expression of IFNGR1 (Figure 4.6A), EZH2 (Figure 4.6B) and the ER 
status. 
 In breast cancer patients, IFNGR1 downregulation in ER
+
 tumors appeared to 
be clinically relevant as it was associated with a poorer distant metastasis free survival 
in the luminal ER
+
 tumors (p=0.00173; Figure 4.6A, Left) but not in basal-like ER
-
 
tumors (p=0.9036; Figure 4.6A, Right). On the contrary, an up-regulation of EZH2 
expression was associated with a poorer DMFS in ER
+
 tumors (p<0.00001; Figure 
4.6B, Left) but not in ER
-
 tumors (p=0.2913; Figure 4.6B, Right). Taken together, the 
results have demonstrated the diagnostic potential of IFNGR1 and EZH2 as 








                  
             
Figure 4.6 Low IFNGR1 and high EZH2 expression in ER+ tumors is associated 
with lower Distant Metastasis Free Survival but not in ER- tumors.  
 A. Kaplan-Meier analyses of distant metastasis free survival (DMFS) of 
  breast cancer patients with low (Grey), intermediate (Red) or high  
  level (Blue) of IFNGR1 expression in ER+ vs. ER- tumors. 
 B. Kaplan-Meier analyses of distant metastasis free survival (DMFS) of 
  breast cancer patients with low (Grey), intermediate (Red) or high  














4.5 EZH2-mediated IFNGR1 silencing in liver cancer is associated 
with cancer progression and high clinical grading. 
 
Apart from advanced prostate cancer and luminal breast cancer, we seek to evaluate if 
EZH2-mediated IFNGR1 silencing could have occur and contributed to oncogenesis 
in other human cancers. Previously, Sudo et al have found that EZH2 was frequently 
overexpressed in hepatocellular carcinoma (HCC) patients. In addition, the incidence 
of cancer cells invading into the hepatic portal vein was significantly higher in 
patients with higher expression of EZH2 (Sudo et al., 2005). In agreement with EZH2 
role in the cancer progression of many other cancers, EZH2 was also found to be 
involved in the progression of HCC too. Upregulation of EZH2 was found to be 
associated with multiple HCC metastatic features which included direct liver invasion 
and the absence of tumor encapsulation. The knockdown of EZH2 in a xenograft 
mouse model of HCC significantly suppressed pulmonary metastasis and showed that 
it was an important driver of metastasis in liver cancer. Therefore, liver cancer was 
chosen to be evaluated for the occurrence of EZH2 mediated repression of IFNGR1.  
 We performed immunohistochemistry (IHC) on a commercially available 
tumor microarray (TMA) slide consisting of 332 HCC cases to study the expression 
of EZH2 and IFNGR1. Quantification of the staining intensity revealed that IFNGR1 
was found to be significantly lower (p<0.001) in the grade III HCC tumors as 
compared to normal liver tissue. In addition, IFNGR1 expression was found to 
decrease as the disease progresses from grade I to grade III (Figure 4.7A&C). On the 
contrary, EZH2 was found to be significantly higher in the grade III HCC tumors as 
compared to the normal liver tissue. Unlike IFNGR1, EZH2 expression was increased 
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as the disease progressed and its expression was inversely correlated to the expression 
of IFNGR1 in the same group of HCC samples (Figure 4.7B&C).  
 Using a panel of HCC cell lines, we characterized the expression of EZH2 and 
IFNGR1 and their response to the combination treatment with DZNep and IFN-γ. 
Western blot analysis showed that the IFNGR1 expression was lower in a majority of 
the 11 HCC cell lines. Two HCC cell lines (PP5 and Huh7) with lower expression of 
IFNGR1 along with two negative control cell lines (HepG2 and Hep3B) with higher 
IFNGR1 expressed were treated with DZNep/IFN-γ combination. As expected, PP5 
and Huh7 after co-treatment with DZNep and IFN-, resulted in a synergistic increase 
in apoptosis. However, this was not observed in the HCC cell lines (HepG2 and 
Hep3B) with high IFNGR1 (Figure 4.8B). Consistent with our prior observations in 
advanced prostate cancer and luminal breast cancer, the results have further 
demonstrated that the IFNGR1 status could stratify and predict for the responsiveness 














                 
Figure 4.7 Inverse association between IFNGR1 and EZH2 in liver cancer and 
was associated to the progression of the disease.  
A-B. Scatter plots generated after quantifying the intensity of immunochemical 
 staining of liver cancer TMA demonstrated an inverse correlation between the 
 protein expression IFNGR1 and EZH2 in liver cancer tumors as the disease 
 progresses in clinical grade. (*p<0.05, **p<0.01, ***p<0.001, n.s.=not 
 significant, two-tailed student’s t-test). 
C. Representative images of the liver cancer TMA-IHC staining (20x 
 magnification) showing the downregulation of IFNGR1 in liver cancer tumors 












Figure 4.8 Depletion of EZH2 with DZNep synergized with IFN-γ to induce 
robust apoptosis in liver cancer cells with low IFNGR1. 
 A. Western blotting analysis showing the downregulation of IFNGR1 in a 
  panel of liver cancer cell lines with high expression of EZH2. 
 B. FACS analysis illustrating the synergistic effect between DZNep and 








4.6 EZH2 mediated IFNGR1 silencing in lung cancer could stratify 
SCLC from NSCLC and predict response to DZNep and IFN-γ 
treatment 
 
Similarly in lung cancer, there were accumulating evidence to implicate EZH2 in the 
cancer progression of lung cancer. EZH2 was found to be overexpressed to various 
subtypes of lung cancers and its high expression is associated with poor prognosis 
(Huqun et al., 2012; Kikuchi et al., 2010). In addition, in vitro studies showed that 
ectopic overexpression of EZH2 resulted in cell cycle deregulation and promoted 
aggressive phenotypes in NSCLC. In agreement with our results, a recent study by 
Byers et al has similarly reported that the expression of EZH2 was much higher in 
SCLC cell lines and primary tumors as compared to the NSCLC samples.     
 Phenotypically, SCLC is an aggressive malignancy which differs from 
NSCLC in terms of its metastatic potential and treatment response. Unlike the more 
common NSCLC, SCLC is more aggressive with a faster rate of proliferation, higher 
growth fraction and faster progression to metastasis. These clinical differences are 
also reflected in their distinct responses to treatment. Although, SCLC is more 
sensitive to chemotherapy and radiation in the early stages of treatment, the disease 
often relapses rapidly and acquired resistance to the treatment. Hence, the 5-year 
survival rate is still less 10% and there is a pressing need for the development of novel 
therapeutic strategies for the treatment of SCLC (Govindan et al., 2006).  
 Interestingly, it was observed that EZH2 was upregulated and IFNGR1 was 
downregulated mainly in the SCLC and distant tumors of metastatic lung cancer 
(Figure 4.9A&B). The similarity in EZH2 and IFNGR1 status shared between SCLC 
and metastatic lung tumors was in agreement with the aggressive clinical nature of 
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SCLC described in previous studies. Likewise, MYC protein was also highly 
expressed in SCLC and metastatic lung cancer which corroborated well with our 
observations in advanced prostate cancer (Figure 4.9C). In addition, meta-analysis of 
EZH2 and IFNGR1 expression in an independent study by Bhattacharjee et al 
revealed a highly similar negative association between EZH2 and IFNGR1 in SCLC 
among 186 primary lung cancer tumors (Bhattacharjee et al., 2001). Downregulation 
of IFNGR1 and upregulation of EZH2 was observed mostly in SCLC as compared to 
other lung cancer subtypes (Figure 4.9D).    
 To validate that lung cancer cell lines with downregulation of IFNGR1 were 
more sensitive to the combined treatment with DZNep and IFN-γ, 5 lung cancer cell 
lines with different expression of IFNGR1 were tested for their response to DZNep 
and/or IFN-γ. Our results revealed that the DZNep and IFN-γ treatment induced a 
significant synergistic increase in apoptosis especially in lung cancer cell lines with 
lower level of IFNGR1 (H460, H2170, H322M and H1299). The data has once again 
demonstrated that the combined DZNep and IFN-γ treatment was more effective in 
lung cancer cell lines showing the higher EZH2 and lower IFNGR1. Taken together, 
these findings suggested that EZH2-mediated IFNGR1 repression could occur in 
subsets of multiple human cancers and the expression levels of EZH2 and IFNGR1 
might be used as a biomarker to identify the patients that may potentially benefit from 











Figure 4.9 Inverse association between EZH2 and IFNGR1 expression in small 
cell lung cancer and specific subset of non small cell lung cancer. 
A-C. Scatter plots generated after quantifying the intensity of immunochemical 
 staining of liver cancer tissue microarray (TMA) illustrating the inverse 
 correlation between the protein expression IFNGR1, EZH2 and MYC in 
 different subtypes of lung cancer tumors. (**p<0.01, ***p<0.001, n.s.=not 
 significant, two-tailed student’s t-test). 
D. Box plots showing the mRNA expression of EZH2 and IFNGR1 in lung 
 cancer tumors from the Bhattacharjee data set (Bhattacharjee et al., 2001). 
 Sample sizes are as indicated in the parentheses. **p<0.01, ***p<0.001 
 
 
             








Figure 4.10 Pharmacological inhibition of EZH2 when combined with IFN-γ 
stimulation induced a synergistic increase in apoptosis in lung cancer cell lines 
with low IFNGR1. 
 A. Western blotting analysis showing the inversely related protein  
  expression of IFNGR1 and EZH2 in a panel of lung cancer cell lines.  
 B. FACS analysis illustrating the synergistic effect between DZNep and 













Figure 4.11 Inverse association between IFNGR1 and EZH2 expression in small 
cell lung cancer and metastatic lung cancer. 
 A. Representative images of the lung cancer TMA-IHC staining showing 
  the downregulation of IFNGR1 in small cell lung cancer tumors with a 
  high level of EZH2. Scale bars= 100 μm  
 B. Representative images of the lung cancer TMA-IHC staining showing 
  the downregulation of IFNGR1 in metastatic lung cancer with a high 


































5.1 Repression of IFNGR1 as a result of a potential epigenetic switch 
induced by the de-regulation of MYC and PI3K signaling in prostate 
cancer  
 
The work presented here identifies a common EZH2 target that may hold therapeutic 
importance in many cancers. By analyzing the MYC-mediated transcriptional 
alteration in prostate cancer cells, a defective IFN-STAT1 signaling pathway was 
found to be suppressed by EZH2 in a MYC-associated manner. It was shown that the 
direct silencing of IFNGR1 by EZH2 mediated the inactivation of this pathway, 
rendering the cancer cells insensitive to IFN-γ treatment. As such, restoration of 
IFNGR1 expression by EZH2 inhibition, either through gene knockdown or 
pharmacologic depletion, sensitizes the ability of IFN-γ to activate the downstream 
STAT1 tumor suppressor pathway, leading to robust apoptosis.   
 In prostate cancer cells, MYC has been previously shown to promote EZH2 
expression through suppression of miR-26a (Koh et al., 2011; Sander et al., 2008). 
Thus, MYC acts upstream of EZH2 and regulates EZH2-mediated IFNGR1 silencing. 
Indeed, the results in this study showed that MYC knockdown mirrored EZH2 
knockdown and that MYC is required for EZH2 and H3K27me3 enrichments in the 
IFNGR1 promoter. Recently, MYC was reported to inhibit the PI3K/AKT signaling 
pathway though PTEN, which in turn led to the stabilization of EZH2 protein and 
increased its activity (Kaur and Cole, 2013). The increase in both EZH2 protein level 
and activity resulted in both local and genome-wide elevation in the repression of its 
target genes. Likewise in this study, it was demonstrated that the level of activated 
AKT (S473 and T387) and the inhibitory S21 phosphorylation of EZH2 were both 
lower in prostate epithelial cells over-expressing MYC as compared to its vector 
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control. Similarly, the EZH2 protein level was also higher in MYC overexpressing 
prostate cells, which is in agreement with what was reported by Kaur and Cole. 
Collectively, these results show that MYC could indirectly increase the activity and 
protein level of EZH2 to enhance the EZH2 mediated repression on its target genes by 
concurrently inhibiting miR-26 and facilitating the inhibition of PI3K/AKT signaling 
pathway.   
 Unlike in MYC transformed cells, it was shown that the constitutive activation 
of the PI3K signaling pathway negatively regulated IFNGR1 expression through an 
alternative mechanism which was independent of EZH2. Instead, there was a 
significant enrichment of methylated CpG islands in the promoter of IFNGR1, 
suggesting that the expression of IFNGR1 could be silenced by promoter DNA 
methylation. Interestingly, it was previously been shown that the MYC and 
PTEN/PI3K/AKT signaling pathway exist in a homeostatic balance to regulate 
proliferation in normal cells, which is often disrupted in cancer cells. Hence, the de-
regulation of MYC and PTEN/PI3K/AKT signaling pathway in prostate cancer could 
confer growth and survival advantages to prostate cancer cells by repressing IFNGR1 











5.2 Targeting EZH2-mediated repression of IFNGR1 as a potential 
therapeutic strategy in MYC-driven advanced prostate cancer 
 
In the past decade, the role of EZH2 in prostate cancer has been aggressively studied 
ever since it was found to be over-expressed in hormone-refractory, metastatic 
prostate cancer (Varambally et al., 2002). Furthermore, localized prostate tumors that 
expressed higher levels of EZH2 showed poorer prognosis which makes it an ideal 
marker that distinguishes those who are at risk of lethal progression from the indolent 
prostate cancer patients. Likewise, it was shown that IFNGR1 downregulation was 
more evident in metastatic prostate tumors as compared to the localized prostate 
tumors and benign prostate tissue. In addition, the decrease in IFNGR1 was found to 
be inversely correlated with the increase in EZH2 expression as the disease progresses 
to metastatic prostate cancer (Figure 3.10-12). In addition, it was observed that the 
IFNGR1 expression also inversely correlated with the MYC expression in a similar 
fashion as EZH2 in the metastatic prostate cancer. Given that MYC is overexpressed 
in up to 30% of advanced prostate cancer (Koh et al., 2010; Sato et al., 1999), and that 
MYC overexpression confers androgen-independency (Bernard et al., 2003; Edwards 
et al., 2003; Nupponen et al., 1998) and metastasis(Bernard et al., 2003; Wolfer et al., 
2010), these findings provide  potential clinical applications for context-dependent 
targeting of MYC-associated refractory prostate cancer that currently lacks effective 
therapy.   
 From a therapeutic point of view, our approach demonstrated the ability of 
EZH2-targeted therapy to reconstitute a pathway dependency that drives drug 
susceptibility. IFN-γ has been previously used to treat advanced prostate cancer with 
disappointing results (Bulbul et al., 1986; Hastie, 2008). Although the reason for this 
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is unknown, our findings suggest that the downregulation of IFNGR1 might provide a 
possible explanation of the lack of efficacy of IFN-γ treatment. Thus, the combination 
approach we identified in this study might have the potential to improve the IFN-γ 
treatment in advanced prostate cancer.  
 Moreover, it was found that a sub-toxic low dose of DZNep and IFN-γ 
induced synergistic antitumor activity in the DU145 xenograft model while not 
displaying overt toxicity to the mice. In fact, we have not observed any significant 
body weight loss with the use of DZNep even when administered together with IFN-γ 
daily for up to 5 weeks. Intriguingly, all xenograft mice that were involved in the 
experiments managed to survive till the end of the study, further highlighting the 
application potential of combination treatment for the treatment of advanced prostate 
cancer. Although DZNep is not an EZH2-H3K27me3 specific inhibitor and may 
affect additional histone methylations or other targets, the remarkable similarity 
between results produced through RNAi-mediated or chemical inhibition strongly 
suggest that DZNep in this scenario acts to recapitulate the EZH2 knockdown to 












5.3 Clinical applications of EZH2-mediated repression of IFNGR1 
for other malignancies beyond prostate cancer 
 
Apart from prostate cancer, EZH2 has been reported to be highly expressed in a wide 
variety of cancer types, including prostate, breast, lung, colon, bladder, pancreatic 
cancer, sarcoma, leukemias and lymphomas. Elevated levels of EZH2 is frequently 
associated with poor prognosis and advanced stages of human cancer progression 
(Sauvageau and Sauvageau, 2010). Similarly, IFNGR1 suppression by EZH2 is not 
restricted to prostate cancer, but occurs widely in many other human cancer types, 
particularly in luminal breast cancer, small cell and metastatic lung cancers, and high 
grade liver cancer that have been validated in this study.  
 In these cancer cells, it was consistently observed that upregulation of EZH2 
coupled with a downregulation of IFNGR1 were associated with profound apoptotic 
response to the combined treatment with EZH2 inhibition and IFN-γ. Thus, the levels 
of EZH2 and IFNGR1 expression could potentially be applied as biomarkers to 
identify patients that may benefit from the combined EZH2 and IFN-γ-based therapy 
in many cancer types. Interestingly, a recent study identifies the silencing of 
interferon regulatory factor IRF7 in breast cancer to be associated with a high risk of 
bone metastasis, which can be inhibited through administration of IFNα (Bidwell et 
al., 2012). Thus, defective IFN signaling pathways in breast cancer, either through the 
loss of  IFNGR1 or IRF7 or both may contribute to both survival and metastasis and 





5.4 The conundrum between depletion of EZH2 and specific 
inhibition of EZH2’s histone methyltransferase activity   
 
In the past decade, there has been a strong interest in the design of EZH2-targeted 
cancer therapies directed towards targeting H3K27me3. Indeed, several specific small 
molecular inhibitors specific for EZH2-induced H3K27me3 were developed and 
showed selective efficacy in lymphomas carrying EZH2 activating mutations that 
cause hyperactive H3K27me3 (Qi et al., 2012) (Knutson et al., 2012; McCabe et al., 
2012; Verma, 2012a). Several pharmaceutical companies such as GlaxoSmithKline 
plc, Epizyme Inc., and Novartis AG have independently launched their small 
molecule EZH2 inhibitors, GSK126 (McCabe et al., 2012), EPZ005687 (Knutson et 
al., 2012) and EI1 (Qi et al., 2012) respectively within the same year in 2012. To date, 
activating EZH2 mutations have not been found in epithelial derived solid tumors; 
thus the anti-cancer activity of the enzymatic inhibitor of EZH2 toward these tumors 
has yet to be determined. Notably, in breast cancer cells, it has been shown that the 
EC50 for growth inhibition was 200-fold higher than that required to deplete the 
cellular H3K27me3 (Verma, 2012a), indicating that inhibiting H3K27me3 alone 
might be insufficient to recapitulate the cellular effects of EZH2 knockdown.  
 Likewise in our study, inhibiting H3K27me3 alone was unable to mimic 
EZH2 knockdown to restore IFNGR1 expression, suggesting that additional 
mechanism(s) might be required to cooperate with H3K27me3 to enforce EZH2-
mediated silencing of IFNGR1. Besides H3K27me3-associated gene silencing, 
recently described “non-canonical” roles of EZH2, such as in activation of NF-κB or 
AR signaling, activation of STAT3 signaling via direct methylation of STAT3 may 
also contribute to oncogenesis (Kim et al., 2013; Lee et al., 2011; Shi et al., 2007; Xu 
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et al., 2012).   Although the specific EZH2 inhibitors could potently inhibit 
H3K27me3 at the promoter of IFNGR1, they are less effective at disrupting the 
binding between EZH2 and the IFNGR1 promoter. On the contrary, DZNep could 
concurrently deplete the enrichment of H3K27me3 and EZH2 within the IFNGR1 
promoter. Hence, DZNep could de-repress the expression of IFNGR1 much more 
effectively as compared to the specific EZH2 inhibitors such as GSK126 or GSK343. 
Consequently, DZNep could effectively restore the expression of IFNGR1 and 
sensitize the prostate cancer cells to apoptosis and growth inhibition induced by IFN-γ 
after 72 hours of treatment. However, this was not observed after co-treating the 
prostate cancer cells with GSK126 and IFN-γ, despite over a prolong duration of 10 
days.   
 Taken together, we envisage that the depletion of EZH2, rather than inhibiting 
H3K27me3 alone, might be necessary for a full phenotypic response. In this regard, 
IFN-γ-induced IFNGR1-STAT1 activation, upon EZH2 knockdown or DZNep 
treatment might be a crucial but not the only contributing mechanism towards the 





































In this study, we have identified IFNGR1 and components of the IFN-γ signaling 
pathway to be down regulated in advanced prostate, lung and liver as well as luminal 
breast cancer. As summarized in Chapter 1.3, the IFN-γ signaling pathway has been 
well studied for its role in coordinating tumor surveillance and mediating anti cancer 
functions. Importantly, we found that the expression of IFNGR1 was inversely 
correlated with the expression of EZH2 and MYC as the disease transits from benign 
prostate tissue to the high grade metastatic prostate cancer. Beyond prostate cancer, 
the down-regulation of IFNGR1 expression was also observed in luminal breast 
cancer cell lines and tumors and low IFNGR1 expression in ER
+
 breast cancer 
patients was associated with shorter distant metastasis free survival post surgery. 
Likewise, IFNGR1 expression was also found to be significantly lower in metastatic 
lung cancer and decreases as the disease progresses in liver cancer. Taken together, 
these clinical observations have implicated the repression of IFNGR1 and IFN-γ 
signaling in the progression of prostate cancer and other human malignancies. As 
such, the repression of IFNGR1 and IFN-γ signaling is a promising therapeutic target 
and could serve as a prognostic biomarker which is clinical relevant in human cancers 
with defective IFN-γ signaling pathway (Figure 6.2). Crucially, we have demonstrated 
the therapeutic potential of restoring of the expression of IFNGR1 by inhibiting EZH2 
both in vitro and in vivo.  
 The basis of restoring the expression of IFNGR1 and the IFN-γ signaling by 
inhibiting EZH2 was first established in our study using prostate cancer as the disease 
model. The mechanism underlying the down-regulation of IFNGR1 and the IFN-γ 
signaling was established in both prostate and luminal breast cancer as summarized in 
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Figure 6.1. Although the expression of IFNGR1 and multiple IFN-γ regulated genes 
were commonly downregulated in both MYC and PI3K transformed prostate cells, the 
underlying repressive mechanisms were different. We found that the expression of 
IFNGR1 in PI3K transformed prostate cells was predominantly silenced by DNA 
methylation of the IFNGR1 promoter. Unlike PI3K transformed cells, the repression 
of IFNGR1 expression in MYC transformed prostate cells was independent of DNA 
methylation and was mediated through EZH2. Previous studies and our results have 
demonstrated that MYC could regulate the expression of EZH2 by inhibiting miR-26a 
(a negative regulator of EZH2 transcriptional expression) or increase the activity of 
EZH2 by inhibiting the S21 phosphorylation of EZH2 mediated by PI3K/AKT 
signaling. S21 phosphorylation of EZH2 has previously been demonstrated to play an 
inhibitory role on EZH2’s activity. The desensitization of the prostate cancer cells to 
IFN-γ stimulation as a result of EZH2 mediated repression of IFNGR1, conferred 
proliferation and survival advantages to promote oncogenesis. Therefore, restoration 
of the IFNGR1 expression by inhibiting EZH2 could enhance the sensitivity of the 
cancer cells to IFN-γ stimulation, leading to more robust apoptosis and growth 
inhibition. 
 In addition, we showed that specific EZH2 inhibitors that solely target the 
histone methyltransferase activity were ineffective in restoring the IFNGR1 
expression and the IFN-γ signaling pathway. Instead, depletion of the EZH2 protein 
by DZNep was much more effective in restoring the expression of IFNGR1 and could 
synergize with IFN-γ treatment to induce a more robust apoptosis in several cell lines 




         
Figure 6.1 EZH2-mediated repression of IFNGR1 expression confers growth and 
survival advantages in cancer cells. 
A mechanistic model showing the expression of IFNGR1 is negatively regulated by 
EZH2 leading to a down regulation of IFN signaling. The overexpression of EZH2 are 
contributed by Myc mediated repression of miR-26a and inhibition on AKT leading 
an increase in EZH2 activity as a result of reduced phosphorylation at S21. An 
increase in both the expression and activity of EZH2 activity drives the gene silencing 
of IFNGR1 resulting in reduced sensitivity and response to IFN-γ stimulation which 




          
Figure 6.2 Combination treatment with DZNep and IFN-γ as an effective 
therapeutic strategy for cancers with EZH2-mediated repression of IFNGR1. 
Diagram illustrating the depletion of EZH2 by DZNep could effectively restore the 
expression of IFNGR1 to sensitize the cancer cells and synergizes with IFN- γ 
treatment to induce apoptosis and inhibit cell proliferation. In contrast, specific 
inhibition of H3K27me3 by specific inhibitors of EZH2 (e.g GSK126 and GSK343) 










6.2 Significance of findings and future work 
This study has successfully identified EZH2 mediated repression of IFNGR1 as a 
prognostic biomarker in several human cancer including advanced prostate, liver and 
liver cancer and luminal breast cancer. Consequently, we have also observed a low 
level of IFNGR1 and high level of EZH2 expression as the disease progresses from 
benign tumor to metastatic disease. This inverse relationship between IFNGR1 and 
EZH2 in both clinical samples and cancer cell lines further supports our hypothesis 
that IFNGR1 is likely a target of EZH2 repression. Importantly, we found that a low 
level of IFNGR1 expression in ER
+
 breast cancer would signify a shorter distant 
metastasis free survival post surgery. As the IFNGR1 expression decreases with 
disease progression, IFNGR1 expression could be developed as a prognostic 
biomarker that may be able to distinguish the aggressive prostate tumors from the 
indolent prostate tumors that do not require active intervention.   
 In addition, our study was the first to report IFNGR1 to be a target of EZH2 
repression and pharmacological inhibition of EZH2 could restore the expression of 
IFNGR1 to synergize with IFN-γ signaling and induce a more robust apoptosis in 
cancer cells. Therapeutically, the strategy of sensitizing cancer cells by restoring the 
expression of IFNGR1 by inhibiting EZH2 could be applied to advanced prostate 
cancer or CRPC patients where treatment options are currently limited. Moreover, our 
preliminary results in Chapter 4 have demonstrated the therapeutic potential of 
combining EZH2 inhibition with IFN-γ stimulation beyond prostate cancer. Hence, 
combination therapy with DZNep and IFN-γ could potentially be applied to other 
human cancers with a defective IFN-γ signaling due the downregulation of IFNGR1 








































Forward Primer 5'-3' Reverse Primer 5'- 3' 
IFNGR1 
P1 TGGTGGGTGCTGTGATTGTG AACCCAGTCTTCTGTTCCTGAGA 
P2 CTTCCTCCGCTCTGCTTCCT GATTAGGGAGTGCTCTTGGAATAAA 
P3 TCAAGACCCAACCTGAATTAGAACT TTAGCTCAGTACTTCTCAAACTTCAACA 
P4 CGCTGAAGGACTTAGCAATGTG GGGTTTGTCTGTTATTTTGCATCTC 
P5 CCCCAGGAAACCGAAAAAA CAACCTGGCACCCCATTC 
P6 GCAGCATGGCTCTCCTCTTT CGCGGTGCCCATCTCA 
P7 CGTCTTCTTACTGTACCTTTTTTTATGG TGCAGGCAACCGTAGCATAC 
P8 GGATTGCCGGCACTCACTA CGAAGAACAAACCCGTACGAA 
STAT1 
ChIP 0 CTCGAGGATCCGATCATTTTAAA GGCAGGCAAAGAGCTTGTG 
ChIP 0.5 GGTGCCGTGGCATCTCTT GCACATCTATTTGTTCTTCTTGTCACA 
ChIP 1 CCAGCGAAGAGTTGGGTGAA GGGACTTCTCACCCTGAGTTTG 
ChIP 1.5 TTGTATGGAGAATGGATTAAAAGGTAGA CTGCAGTAGATTCCCGAATGG 
ChIP 2 GGAGAGGTGTGGACGGGATA TCACCCACAGCTTCAGTTTCC 
ChIP 3 CTGGATTCTCGGCGATGAA TGTGTTTGCAGAAGCCCAAA 
ChIP 4 GCCACCTGTTCTCGGAGATG AGAGCACGACTGGCAAGGA 
MX1 
ChIP-2 GGTTGCCCAGCCCTAGGA CAGCTCCCTGTGCTGAAATCT 
ChIP-1.5 CCCGTGACAATTCTGAGGAAA CCCTAGTCCAGCTTGGAGGAT 
ChIP-1 TCCTTCCACACACCCGTTTC TCCCTGGAGTCTGGCTCATC 
ChIP-0.5 ATACGTGCAGGCTTGGATGAC AGGCCCGTCTGAGGATCAA 
ChIP+0.5 GATGCTAACCGCGCCTCTAC AGCCATTTTAGGAGCCCTTTG 
IRF1 
ChIP-2 TTTTTATAGTGTCCTGTTGCCTTCA GAAGTTTGCATCTTTGTGGTCTGA 
ChIP-1.5 GGTCACAGCACTCAGATTGCA CCCTCCCGTAGAGGAAATGC 
ChIP-1 CAGCCGTCTGGGCTTCTC CCCCTGGCTGGCTTTAGG 
ChIP-0.5 CCCTTCGCCGCTAGCTCTA TGCGTGCCGTCATTTCG 
ChIP-0 AAGGGTTAGCGTCCTGGTCTTAG CCATTCTACGCCTTCCTGAC 
OAS1 
ChIP-2 CCACAAAAGAAAGATAGCTGGAAAA TCTTCCTTGCCCCATGTGTT 
ChIP-1.5 TCACATTCATACCCACTTTTAAATACG CCAGTTACCACCCTTCTTCTAGAAA 
ChIP-1 AAAAATGAGCTGGGTGCAGTAAC GCCCCAGCCTCCTGAATAC 
ChIP-0.5 AGAGGCAATTTTGTAGTGTTAGAATCAT CACTGCAAAAAGAAAAAAAGTCAGAA 
ChIP+0.5 GCACCTGCTGGCTGCAA TGAGGAAATTGGAACACAGAGTAGTT 
Table 7.1. Primers specific to promoter regions of IFNGR1 and IFN-γ regulated genes used for 
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